

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/104222 A1

(51) International Patent Classification⁷: **C07D 401/14**,
403/14, 409/14, A61K 31/404, 31/4025, 31/4439, 31/506,
A61P 7/02, 9/00, 17/00, 25/00, 37/00, 35/00

(74) Agents: **JOHNSON,, Philip, S. et al.**; JOHNSON
& JOHNSON, One Johnson & Johnson Plaza, New
Brunswick, NJ 08933 (US).

(21) International Application Number: PCT/US03/17569

(22) International Filing Date: 4 June 2003 (04.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/385,935 5 June 2002 (05.06.2002) US

(71) Applicant (*for all designated States except US*):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-
houtseweg 30, B-B2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ZHANG, Han-Cheng** [US/US]; 109 Bryan Way, Lansdale, PA 19446 (US). **MARYANOFF, Bruce, E.** [US/US]; 4029 Devonshire Drive, Forest Grove, PA 18922 (US). **YE, Hong** [US/US]; 124 Canterbury Lane, Lansdale, PA 19446 (US). **CONWAY, Bruce, R.** [US/US]; 3302 Ephross Circle, Doylestown, PA 18901 (US). **DEMAREST, Keith** [US/US]; 1 Newell Road, Flemington, NJ 08822 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BISINDOLYL-MALEIMID DERIVATIVES AS KINASE INHIBITORS



(57) Abstract: The present invention is directed to novel substituted pyrroline compounds of Formula (I) wherein R¹ is selected from the group consisting of a pyridinyl-R⁵, pyrimidinyl-R⁵, pyrazinyl-R⁵, furyl-R⁵, thienyl-R⁵, benzofuryl-R⁵, benzothienyl-R⁵, quinolinyl-R⁵ and isoquinolinyl-R⁵ ring attached to the indole nitrogen atom via a ring carbon atom; useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder such as cardiovascular, inflammatory, immunological, dermatological, oncological, CNS disorders and diabetes.

SUBSTITUTED PYRROLINES AS KINASE INHIBITORS


FIELD OF THE INVENTION

This application claims benefit from provisional patent application 60/385,935 filed on June 5, 2002, which is hereby incorporated by reference herein.





This invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase or dual-kinase mediated disorder. More particularly, this invention is directed to substituted pyrroline compounds useful as selective kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

BACKGROUND OF THE INVENTION

United States Patent 5,057,614 to Davis, et. al., describes substituted pyrrole compounds of formula I as therapeutically active substances for the use in control or prevention of inflammatory, immunological, bronchopulmonary and cardiovascular disorders:



acylthioalkyl, alkylsulphonylaminoalkyl, arylsulphonylaminoalkyl, mercaptoalkyl, alkylthioalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl, alkylsulphonyloxyalkyl, alkylcarbonyloxyalkyl, cyanoalkyl, amidinoalkyl, isothiocyanatoalkyl, glucopyranosyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl,
 5 hydroxyalkylthioalkyl, mercaptoalkylthioalkyl, arylthioalkyl or carboxyalkylthioalkyl or a group of the formula:




in which Het signifies a heterocyclyl group, W signifies NH, S or a bond, T signifies NH or S, V signifies O, S, NH, NNO_2 , NCN or CHNO_2 , Z signifies alkylthio, amino, monoalkylamino or dialkylamino, Im signifies 1-imidazolyl, Ar
 10 signifies aryl, and n stands for 2-6; R^2 signifies hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, alkylsulphonylaminoalkyl, arylsulphonylaminoalkyl, mercaptoalkyl, alkylthioalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylthio or alkylsulphinyl; R^3 signifies
 15 a carbocyclic or heterocyclic aromatic group; R^4 , R^5 , R^6 and R^7 each independently signify hydrogen, halogen, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, acylamino, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or alkylsulphonyl; and one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); with the proviso that R^1 has a significance different from
 20 hydrogen when R^2 signifies hydrogen, R^3 signifies 3-indolyl or 6-hydroxy-3-indolyl, R^4 , R^5 and R^7 each signify hydrogen, R^6 signifies hydrogen or hydroxy and X and Y both signify O and when R^2 signifies hydrogen, R^3 signifies 3-indolyl, R^4 , R^5 , R^6 and R^7 each signify hydrogen, X signifies (H,H) and Y signifies O; as well as pharmaceutically acceptable salts of acidic
 25 compounds of formula I with bases and of basic compounds of formula I with acids; wherein the R^3 carbocyclic aromatic group is defined as a monocyclic or polycyclic group, preferably a monocyclic or bicyclic group such as phenyl or naphthyl which can be unsubstituted or substituted with 1 or more, preferably 1 to 3, substituents selected from halogen, unsubstituted C_{1-7} alkyl, hydroxy,

unsubstituted C₁₋₇alkoxy, (halo)₁₋₃(C₁₋₇)alkyl, nitro, amino, acylamino,
 monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or alkylsulfonyl; wherein
 the R³ carbocyclic aromatic group is selected from phenyl, 2-, 3- or
 4-chlorophenyl, 3-bromophenyl, 2- or 3-methylphenyl, 2,5-dimethylphenyl,
 5 4-methoxyphenyl, 2- or 3-trifluoromethylphenyl, 2-, 3- or 4-nitrophenyl, 3- or
 4-aminophenyl, 4-methylthiophenyl, 4-methylsulphinylphenyl,
 4-methylsulphonylphenyl or 1- or 2-naphthyl; wherein the R³ heterocyclic
 aromatic group is defined as a 5- or 6-membered heterocyclic aromatic group
 optionally fused with a benzene ring and substituted or unsubstituted with 1 or
 10 more, preferably 1 to 3, substituents selected from halogen, (C₁₋₇)alkyl,
 hydroxy, (C₁₋₇)alkoxy, (C₁₋₇)alkyl-halo, nitro, amino, -NH-C(O)-(C₁₋₇)alkyl,
 -NH(C₁₋₇alkyl), -N(C₁₋₇alkyl)₂, -S-(C₁₋₇)alkyl, -C(SO)-(C₁₋₇)alkyl or
 -SO₂-(C₁₋₇)alkyl; wherein the R³ heterocyclic aromatic group is 2- or 3-thienyl,
 3-benzothienyl, 1-methyl-2-pyrrolyl, 1-benzimidazolyl, 3-indolyl, 1- or
 15 2-methyl-3-indolyl, 1-methoxymethyl-3-indolyl, 1-(1-methoxyethyl)-3-indolyl,
 1-(2-hydroxypropyl)-3-indolyl, 1-(4-hydroxybutyl)-3-indolyl,
 1-[1-(2-hydroxyethylthio)ethyl]-3-indolyl,
 1-[1-(2-mercaptoethylthio)ethyl]-3-indolyl, 1-(1-phenylthioethyl)-3-indolyl,
 1-[1-(carboxymethylthio)ethyl]-3-indolyl or 1-benzyl-3-indolyl; and, when the R³
 20 heterocyclic aromatic group is 3-indolyl, the 3-indolyl nitrogen atom is
 substituted with a substituent selected from hydrogen, C₁₋₇alkyl, aryl (wherein
 aryl is phenyl unsubstituted or substituted with 1 or more, preferably 1 to 3,
 substituents selected from halogen, unsubstituted C₁₋₇alkyl, hydroxy,
 unsubstituted C₁₋₇alkoxy, (halo)₁₋₃(C₁₋₇)alkyl, nitro, amino, acylamino,
 25 monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or alkylsulfonyl),
 -(C₁₋₇)alkyl-aryl (wherein aryl is phenyl unsubstituted or substituted with 1 or
 more, preferably 1 to 3, substituents selected from halogen, unsubstituted
 C₁₋₇alkyl, hydroxy, unsubstituted C₁₋₇alkoxy, (halo)₁₋₃(C₁₋₇)alkyl, nitro, amino,
 acylamino, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or
 30 alkylsulfonyl), -(C₁₋₇)alkyl(C₁₋₇)alkoxy, -(C₁₋₇)alkyl-hydroxy, -(C₁₋₇)alkyl-(halo)₁₋₃,

- (C₁₋₇)alkyl-NH₂, -(C₁₋₇)alkyl-NH(C₁₋₇alkyl), -(C₁₋₇)alkyl-N(C₁₋₇alkyl)₂,
 -(C₁₋₇)alkyl-N⁺(C₁₋₇alkyl)₃, -(C₁₋₇)alkyl-NH(C₁₋₇alkyl)NH₂, -(C₁₋₇)alkyl-N₃,
 -C₁₋₇alkyl-NH-C(O)-(C₁₋₇)alkyl, -C₁₋₇alkyl-S-C(O)-(C₁₋₇)alkyl,
 -C₁₋₇alkyl-NH-SO₂-(C₁₋₇)alkyl, -C₁₋₇alkyl-NH-SO₂-aryl (wherein aryl is phenyl
 5 unsubstituted or substituted with 1 or more, preferably 1 to 3, substituents
 selected from halogen, unsubstituted C₁₋₇alkyl, hydroxy, unsubstituted
 C₁₋₇alkoxy, (halo)₁₋₃(C₁₋₇)alkyl, nitro, amino, acylamino, monoalkylamino,
 dialkylamino, alkylthio, alkylsulphinyl or alkylsulfonyl), -(C₁₋₇)alkyl-SH,
 -(C₁₋₇)alkyl-S-(C₁₋₇)alkyl, -(C₁₋₇)alkyl-C(SO)-(C₁₋₇)alkyl,
 10 -(C₁₋₇)alkyl-SO₂-(C₁₋₇)alkyl, -(C₁₋₇)alkyl-O-SO₂-(C₁₋₇)alkyl,
 -(C₁₋₇)alkyl-O-C(O)-(C₁₋₇)alkyl, -(C₁₋₇)alkyl-C(N), -(C₁₋₇)alkyl-C(NH)-NH₂,
 glucopyranosyl, -(C₁₋₇)alkyl-CO₂H, -(C₁₋₇)alkyl-C(O)-O-(C₁₋₇)alkyl,
 -(C₁₋₇)alkyl-C(O)-NH₂, -(C₁₋₇)alkyl-S-(C₁₋₇)alkyl-OH, -(C₁₋₇)alkyl-S-(C₁₋₇)alkyl-SH,
 -C₁₋₇alkyl-S-aryl (wherein aryl is phenyl unsubstituted or substituted with 1 or
 15 more, preferably 1 to 3, substituents selected from halogen, unsubstituted
 C₁₋₇alkyl, hydroxy, unsubstituted C₁₋₇alkoxy, (halo)₁₋₃(C₁₋₇)alkyl, nitro, amino,
 acylamino, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or
 alkylsulfonyl), -(C₁₋₇)alkyl-S-(C₁₋₇)alkyl-CO₂H, -(CH₂)₂₋₆-W-Het (wherein W is
 selected from NH, S or a bond; wherein Het is a saturated, partially saturated
 20 or aromatic 5- or 6-membered heterocyclic group optionally fused with a
 benzene ring and substituted or unsubstituted with 1 or more, preferably 1 to 3,
 substituents selected from halogen, (C₁₋₇)alkyl, hydroxy, (C₁₋₇)alkoxy,
 (C₁₋₇)alkyl-halo, nitro, amino, -NH-C(O)-(C₁₋₇)alkyl, -(C₁₋₇)alkyl-NH(C₁₋₇alkyl),
 -(C₁₋₇)alkyl-N(C₁₋₇alkyl)₂, -S-(C₁₋₇)alkyl, -C(SO)-(C₁₋₇)alkyl or -SO₂-(C₁₋₇)alkyl;
 25 wherein when Het is an aromatic nitrogen-containing heterocyclic group, a
 nitrogen atom may be substituted with an oxide group; and, wherein Het is
 selected from imidazolyl, imidazolynyl, thiazolynyl, pyridyl or pyrimidinyl),
 -(CH₂)₂₋₆-T-C(V)-Z (wherein T is selected from NH or S; V is selected from O,
 S, NH, NNO₂, NCN or CHNO₂; and, Z is selected from -S-(C₁₋₇)alkyl, NH₂,
 30 NH(C₁₋₇alkyl) or N(C₁₋₇alkyl)₂), -(CH₂)₂₋₆-NH-C(O)-1-imidazolyl or


-(CH₂)₂₋₆-NH-C(=NH)-aryl (wherein aryl is phenyl unsubstituted or substituted
 with 1 or more, preferably 1 to 3, substituents selected from halogen,
 unsubstituted C₁₋₇alkyl, hydroxy, unsubstituted C₁₋₇alkoxy, (halo)₁₋₃(C₁₋₇)alkyl,
 nitro, amino, acylamino, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl
 5 or alkylsulfonyl).

United States Patent 6,037,475 to Faul, et. al., describes a method of
 making an N-substituted indolylmaleimide of formula I as therapeutically active
 substances for the use in control or prevention of inflammatory, immunological,
 10 bronchopulmonary and cardiovascular disorders:




formula I

using an organometallic reagent and an optionally substituted activated
 organometallic-3-indole maleimide in the presence of a palladium transition
 metal catalyst wherein R² is selected from a leaving group and an optionally
 substituted indol-3-yl, R³ is selected from hydrogen and a protecting group,
 15 R⁷'s are hydrogen or up to four optional substituents independently selected
 from halo, alkyl, hydroxy, alkoxy, haloalkyl, nitro, -NHCO(alkyl), or -NR⁹R¹⁰;
 where R⁹ and R¹⁰ are independently hydrogen, or methyl, R⁸ is hydrogen or an
 optional substituent selected from, alkyl, haloalkyl, alkenyl, arylalkyl,
 alkoxyalkyl, hydroxyalkyl, monoalkylaminoalkyl, dialkylaminoalkyl,
 20 acylaminoalkyl, acyloxyalkyl, cyanoalkyl, amidinoalkyl, carboxyalkyl,
 alkoxycarbonylalkyl, aminocarbonylalkyl, aryl, alkylaryl, aminoalkyl, heteroaryl,
 carbonylalkyl, amidinothioalkyl, nitroguanidinoalkyl, a protecting group, an
 alkylglycose residue, or a group of the formula:




- in which Het signifies a heterocyclyl group, W signifies NH, S or a bond, T signifies NH or S, V signifies O, S, NH or NCN, A signifies alkylthio, amino, monoalkylamino or dialkylamino, and Ar signifies aryl; R¹⁶ is hydrogen, alkyl, haloalkyl, acetyl, aryl, -CH(aryl)₂, amino, monoalkylamino, dialkylamino, guanidino, -C(=N(alkoxy-carbonyl))-NH-(alkoxycarbonyl), amidino, hydroxy, carboxy, alkoxycarbonyl or heterocyclyl; R¹⁴ is hydrogen or an optionally substituted alkyl; or R⁸ and R¹⁴ are linked together through a group of the formula $\text{-(CH}_2\text{)}_r\text{-X-(CH}_2\text{)-}$ where X is $\text{-(C(-(CH}_2\text{)}_6\text{-R}^{17}\text{))(-(CH}_2\text{)}_6\text{-R}^{18}\text{))}$ where R¹⁷ and R¹⁸ are independently hydroxy, carboxy, acyloxy, amino, monoalkylamino, dialkylamino, trialkylamino, azido, acylamino, cyano, amidino or aminocarbonyl, and n is 1, 2, 3, 4, 5 or 6, p and q are 1, 2, 3 or 4, r is 1, 2 or 3, s is 0, 1, 2 or 3, t is 1 or 2, and u is 0 or 1.

- United States Patent 5,721,245 to Davis, et. al., describes substituted 4-[3-indolyl]-1H-pyrrolone compounds of formula I:




- wherein R is hydrogen or hydroxy, R¹ and R² taken together are a group of the formula $-(CH_2)_n-$ and R⁷ is hydrogen or R¹ and R⁷ taken together are a group of the formula $-(CH_2)_n-$ and R² is hydrogen; R³ is an aryl or aromatic
- 5 heterocyclic group; R⁴, R⁵ and R⁶ each independently are hydrogen, halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, alkylthio, alkylsulfinyl or alkylsulfonyl; R⁸ is a group of the formula $-(CH_2)_p-R^9$ or $-(CH_2)_q-R^{10}$; R⁹ is hydrogen, alkylcarbonyl, aminoalkylcarbonyl, cyano, amidino, alkoxy carbonyl, aryloxy carbonyl, alkylsulfonyl, aminocarbonyl or aminothiocarbonyl; R¹⁰ is
- 10 hydroxy, alkoxy, halogen, amino, monoalkylamino, dialkylamino, trialkylamino, azido, acylamino, alkylsulfonylamino, arylsulfonylamino, alkylthio, alkoxy carbonylamino, aminoacylamino, aminocarbonylamino, isothiocyanato, alkylcarbonyloxy, alkylsulfonyloxy or arylsulfonyloxy, a 5- or 6-membered saturated nitrogen-containing heterocycle attached via the nitrogen atom or a
- 15 group of the formula $-U-C(V)-W$; U is S or NH; V is NH, NNO₂, NCN, CHNO₂; W is amino, monoalkylamino or dialkylamino; one of X and Y is O and the other is O or (H,H); Z is CH or N; m, p and q are, independently, an integer from 0 to 5, and n is an integer from 1 to 5, with the proviso that q and m are, independently, 2 to 5 when Z is N; as well as pharmaceutically acceptable salts
- 20 of acidic compounds of formula I with bases and of basic compounds of formula I with acids, as therapeutically active substances for use in control or prevention of inflammatory, immunological, bronchopulmonary and cardiovascular disorders.

United States Patent 5,624,949 to Heath, Jr., et. al., describes bis-indolemaleimide derivatives of the formula:



wherein W is -O-, -S-, -SO-, -SO₂-, -CO-, C₂-C₆ alkylene, substituted alkylene, C₂-C₆ alkenylene, -aryl-, -aryl(CH₂)_mO-, -heterocycle-, -heterocycle-(CH₂)_mO-,
 5 -fused bicyclic-, -fused bicyclic-(CH₂)_mO-, -NR₃-, -NOR₃-, -CONH- or -NHCO-; X and Y are independently C₁-C₄ alkylene, substituted alkylene, or together, X, Y and W combine to form (CH₂)_n-AA-; R₁ is independently hydrogen, halo, C₁-C₄ alkyl, hydroxy, C₁-C₄ alkoxy, haloalkyl, nitro, NR₄R₅ or -NHCO(C₁-C₄)alkyl; R₂ is
 10 hydrogen, CH₃CO-, NH₂ or hydroxy; R₃ is hydrogen, (CH₂)_maryl, C₁-C₄ alkyl, -COO(C₁-C₄ alkyl), -CONR₄R₅, -C(C=NH)NH₂, -SO(C₁-C₄ alkyl), -SO₂(NR₄R₅) or -SO₂(C₁-C₄ alkyl); R₄ and R₅ are independently hydrogen, C₁-C₄ alkyl, phenyl, benzyl, or combine to the nitrogen to which they are bonded to form a saturated or unsaturated 5 or 6 member ring; AA is an amino acid residue; m is
 15 independently 0, 1, 2 or 3; and n is independently 2, 3, 4 or 5 as protein kinase C (PKC) inhibitors and as selective PKCβ-I and PKCβ-II inhibitors.

Patent application WO 00/06564 discloses disubstituted maleimide compounds of Formula (I):




20

wherein R¹ represents hydrogen or alkyl; R² represents aryl, cycloalkyl or a

heterocycle; R^3 , R^5 , R^6 , R^7 and R^8 represent each hydrogen, halogen, hydroxy, amino, alkyl or alkoxy; and R^4 is W, or R^4 and R^3 or R^4 and R^5 may form together a ring substituted by W thereon; wherein W represents $-(CH_2)_l-(Y)_m-(CH_2)_n-Z$ as PKC β inhibitors.

5

Patent application WO 00/21927 describes 3-amino-4-arymaleimide compounds having formula (I):



or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl or aralkyl; R^1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R^2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R^3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R^1 and R^3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocyclic ring and a method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression.

20

The substituted pyrroline compounds of the present invention have not been heretofore disclosed.

Accordingly, it is an object of the present invention to provide substituted pyrroline compounds useful as a kinase or dual-kinase inhibitor (in particular, a kinase selected from protein kinase C or glycogen synthase kinase-3; and, more particularly, a kinase selected from protein kinase C α , protein kinase C


25

β -II, protein kinase C γ or glycogen synthase kinase-3 β), methods for their production and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

5

SUMMARY OF THE INVENTION

The present invention is directed to substituted pyrroline compounds of Formula (I):



Formula (I)

wherein

- 10 R^1 is selected from a pyridinyl- R^5 , pyrimidinyl- R^5 , pyrazinyl- R^5 , furyl- R^5 , thienyl- R^5 , benzofuryl- R^5 , benzothienyl- R^5 , quinoliny- R^5 or isoquinoliny- R^5 ring attached to the indole nitrogen atom via a ring carbon atom;

- R^5 is up to 4 substituents independently selected from hydrogen,
- 15 $-(C_{1-8})\text{alkyl-}R^6$, $-(C_{2-8})\text{alkenyl-}R^6$, $-(C_{2-8})\text{alkynyl-}R^6$, $-O-(C_{1-8})\text{alkyl-}R^6$, $-O-C(O)H$, $-O-C(O)-(C_{1-8})\text{alkyl-}R^6$, $-O-C(O)-NH_2$, $-O-C(O)-NH(C_{1-8}\text{alkyl})$, $-O-C(O)-N(C_{1-8}\text{alkyl})_2$, $-C(O)H$, $-C(O)-(C_{1-8})\text{alkyl-}R^6$, $-CO_2H$, $-C(O)-O-(C_{1-8})\text{alkyl-}R^6$, $-C(O)-NH_2$, $-C(NH)-NH_2$, $-C(O)-NH(C_{1-8}\text{alkyl})$, $-C(O)-N(C_{1-8}\text{alkyl})_2$, $-SH$, $-S-(C_{1-8})\text{alkyl-}R^6$, $-SO_2-(C_{1-8})\text{alkyl-}R^6$, $-SO_2-NH_2$,
- 20 $-SO_2-NH(C_{1-8}\text{alkyl})$, $-SO_2-N(C_{1-8}\text{alkyl})_2$, $-N-R^7$, cyano, halo, hydroxy, nitro, $-cycloalkyl-R^8$, $-heterocyclyl-R^9$, $-aryl-R^8$ or $-heteroaryl-R^9$;

R^6 is up to 2 substituents independently selected from hydrogen, $-O-(C_{1-8})\text{alkyl}$,

-O-(C₁₋₈)alkyl-OH, -O-(C₁₋₈)alkyl-NH₂, -O-(C₁₋₈)alkyl-NH(C₁₋₈alkyl),
 -O-(C₁₋₈)alkyl-N(C₁₋₈alkyl)₂ -C(O)H, -C(O)-(C₁₋₈)alkyl, -CO₂H,
 -C(O)-O-(C₁₋₈)alkyl, -C(O)-NH₂, -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂,
 -S-(C₁₋₈)alkyl, -SO₂-(C₁₋₈)alkyl, -SO₂-NH₂, -SO₂-NH(C₁₋₈alkyl),
 5 -SO₂-N(C₁₋₈alkyl)₂, -N-R⁷, cyano, (halo)₁₋₃, hydroxy, nitro, oxo, -cycloalkyl,
 -heterocyclyl, -aryl or -heteroaryl;

R⁷ is 2 substituents independently selected from hydrogen, -(C₁₋₈)alkyl-R¹⁰,
 -(C₂₋₈)alkenyl-R¹⁰, -(C₂₋₈)alkynyl-R¹⁰, -C(O)-(C₁₋₈)alkyl-R¹⁰,
 10 -C(O)-O-(C₁₋₈)alkyl-R¹⁰, -C(O)-NH₂, -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂,
 -SO₂-(C₁₋₈)alkyl, -SO₂-NH₂, -SO₂-NH(C₁₋₈alkyl), -SO₂-N(C₁₋₈alkyl)₂,
 -C(N)-NH₂, -cycloalkyl-R⁸, -heterocyclyl-R⁹, -aryl-R⁸ or -heteroaryl-R⁹;

R⁸ is up to 5 substituents independently selected from hydrogen, -C₁₋₈alkyl,
 15 -C₁₋₈alkoxy, -NH₂, -NH(C₁₋₈alkyl), -N(C₁₋₈alkyl)₂, -(C₁₋₈)alkyl-(halo)₁₋₃,
 -(C₁₋₈)alkoxy-(halo)₁₋₃, -(C₁₋₈)alkyl-OH, cyano, halo, hydroxy or nitro;

R⁹ is up to 5 substituents attached to a carbon or nitrogen atom independently
 selected from hydrogen, -C₁₋₈alkyl, -(C₁₋₈)alkyl-(halo)₁₋₃ or -(C₁₋₈)alkyl-OH;
 20 with the proviso that, when R⁹ is attached to a carbon atom, R⁹ is further
 selected from -C₁₋₈alkoxy, -NH₂, -NH(C₁₋₈alkyl), -N(C₁₋₈alkyl)₂,
 -(C₁₋₈)alkoxy-(halo)₁₋₃, cyano, halo, hydroxy or nitro;

R² is selected from -C₁₋₈alkyl-R⁶, -C₂₋₈alkenyl-R⁶, -C₂₋₈alkynyl-R⁶, -C(O)H,
 25 -C(O)-(C₁₋₈)alkyl-R⁶, -C(O)-NH₂, -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂,
 -C(O)-NH(aryl), -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-aryl,
 -C(O)-heteroaryl, -CO₂H, -C(O)-O-(C₁₋₈)alkyl-R⁶, -C(O)-O-aryl,
 -SO₂-(C₁₋₈)alkyl-R⁶, -SO₂-aryl, -cycloalkyl-R⁸, -heterocyclyl-R⁹ (attached to
 the indole nitrogen atom via a ring carbon atom), -aryl-R⁸ or -heteroaryl-R⁹
 30 (attached to the indole nitrogen atom via a ring carbon atom);

R³ is up to 4 substituents attached to a carbon atom independently selected from hydrogen, -C₁₋₈alkyl-R¹⁰, -C₂₋₈alkenyl-R¹⁰, -C₂₋₈alkynyl-R¹⁰, -C₁₋₈alkoxy-R¹⁰, -C(O)H, -C(O)-(C₁₋₈alkyl)-R¹⁰, -C(O)-NH₂, -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -C(O)-cycloalkyl,
 5 -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(NH)-NH₂, -CO₂H, -C(O)-O-(C₁₋₈alkyl)-R¹⁰, -C(O)-O-aryl, -SO₂-(C₁₋₈alkyl)-R¹⁰, -SO₂-aryl, -N-R⁷, cyano, halogen, hydroxy, nitro, -cycloalkyl, -heterocyclyl, -aryl or -heteroaryl;

R⁴ is up to 4 substituents attached to a carbon atom independently selected from hydrogen, -C₁₋₈alkyl-R¹⁰, -C₂₋₈alkenyl-R¹⁰, -C₂₋₈alkynyl-R¹⁰,
 10 -C₁₋₈alkoxy-R¹⁰, -C(O)H, -C(O)-(C₁₋₈alkyl)-R¹⁰, -C(O)-NH₂, -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(NH)-NH₂, -CO₂H, -C(O)-O-(C₁₋₈alkyl)-R¹⁰, -C(O)-O-aryl, -SH, -S-(C₁₋₈alkyl)-R¹⁰,
 15 -SO₂-(C₁₋₈alkyl)-R¹⁰, -SO₂-aryl, -SO₂-NH₂, -SO₂-NH(C₁₋₈alkyl), -SO₂-N(C₁₋₈alkyl)₂, -N-R⁷, cyano, halogen, hydroxy, nitro, -cycloalkyl, -heterocyclyl, -aryl or -heteroaryl; and,

R¹⁰ is 1 to 2 substituents independently selected from hydrogen, -C₁₋₈alkoxy,
 20 -NH₂, -NH(C₁₋₈alkyl), -N(C₁₋₈alkyl)₂, cyano, (halo)₁₋₃, hydroxy, nitro or oxo;

and pharmaceutically acceptable salts thereof.

The present invention is directed to substituted pyrroline compounds
 25 useful as a selective kinase or dual-kinase inhibitor; in particular, a kinase selected from protein kinase C or glycogen synthase kinase-3; and, more particularly, a kinase selected from protein kinase C α , protein kinase C β (e.g. protein kinase C β -I and protein kinase C β -II), protein kinase C γ or glycogen synthase kinase-3 β .

30

The present invention is also directed to methods for producing the

instant substituted pyrroline compounds and pharmaceutical compositions and medicaments thereof.

The present invention is further directed to methods for treating or
5 ameliorating a kinase or dual-kinase mediated disorder.

DETAILED DESCRIPTION OF THE INVENTION

Aspects of the present invention include compounds of Formula (I)
10 wherein R¹ is selected from a pyridinyl-R⁵, pyrimidinyl-R⁵, furyl-R⁵, thienyl-R⁵, benzothienyl-R⁵ or quinolinyl-R⁵ ring attached to the indole nitrogen atom via a ring carbon atom and preferably wherein R¹ is selected from a pyridinyl-R⁵, pyrimidinyl-R⁵, benzothienyl-R⁵ or quinolinyl-R⁵ ring attached to the indole nitrogen atom via a ring carbon atom.

15

Aspects of the present invention include compounds of Formula (I) wherein R⁵ is up to 4 substituents independently selected from hydrogen, -(C₁₋₄)alkyl-R⁶, -(C₂₋₄)alkenyl-R⁶, -(C₂₋₄)alkynyl-R⁶, -O-(C₁₋₄)alkyl-R⁶, -O-C(O)H, -O-C(O)-(C₁₋₄)alkyl-R⁶, -O-C(O)-NH₂, -O-C(O)-NH(C₁₋₄alkyl),
20 -O-C(O)-N(C₁₋₄alkyl)₂, -C(O)H, -C(O)-(C₁₋₄)alkyl-R⁶, -CO₂H, -C(O)-O-(C₁₋₄)alkyl-R⁶, -C(O)-NH₂, -C(NH)-NH₂, -C(O)-NH(C₁₋₄alkyl), -C(O)-N(C₁₋₄alkyl)₂, -SH, -S-(C₁₋₄)alkyl-R⁶; -SO₂-(C₁₋₄)alkyl-R⁶, -SO₂-NH₂, -SO₂-NH(C₁₋₄alkyl), -SO₂-N(C₁₋₄alkyl)₂, -N-R⁷, cyano, halo, hydroxy, nitro, -cycloalkyl-R⁸, -heterocyclyl-R⁹, -aryl-R⁸ or -heteroaryl-R⁹.

25

Another aspect of the present invention includes compounds of Formula (I) wherein R⁵ is up to 4 substituents independently selected from hydrogen or -(C₁₋₄)alkyl-R⁶.

30

A further aspect of the present invention includes compounds of Formula (I) wherein R⁵ is 1 substituent selected from hydrogen or

-(C₁₋₄)alkyl-R⁶.

Aspects of the present invention include compounds of Formula (I) wherein R⁶ is up to 2 substituents independently selected from hydrogen,
 5 -O-(C₁₋₄)alkyl, -O-(C₁₋₄)alkyl-OH, -O-(C₁₋₄)alkyl-NH₂, -O-(C₁₋₄)alkyl-NH(C₁₋₄)alkyl,
 -O-(C₁₋₄)alkyl-N(C₁₋₄)alkyl)₂, -C(O)H, -C(O)-(C₁₋₄)alkyl, -CO₂H,
 -C(O)-O-(C₁₋₄)alkyl, -C(O)-NH₂, -C(O)-NH(C₁₋₄)alkyl, -C(O)-N(C₁₋₄)alkyl)₂,
 -S-(C₁₋₄)alkyl, -SO₂-(C₁₋₄)alkyl, -SO₂-NH₂, -SO₂-NH(C₁₋₄)alkyl),
 -SO₂-N(C₁₋₄)alkyl)₂, -N-R⁷, cyano, (halo)₁₋₃, hydroxy, nitro, oxo, -cycloalkyl,
 10 -heterocyclyl, -aryl or -heteroaryl.

Another aspect of the present invention includes compounds of Formula (I) wherein R⁶ is up to 2 substituents independently selected from hydrogen,
 -N-R⁷, hydroxy or -heteroaryl.
 15

A further aspect of the present invention includes compounds of Formula (I) wherein R⁶ is up to 2 substituents independently selected from hydrogen, -N-R⁷, hydroxy or -tetrazolyl.

Aspects of the present invention include compounds of Formula (I) wherein R⁷ is 2 substituents independently selected from hydrogen,
 20 -(C₁₋₄)alkyl-R¹⁰, -(C₂₋₄)alkenyl-R¹⁰, -(C₂₋₄)alkynyl-R¹⁰, -C(O)-(C₁₋₄)alkyl-R¹⁰,
 -C(O)-O-(C₁₋₄)alkyl-R¹⁰, -C(O)-NH₂, -C(O)-NH(C₁₋₄)alkyl, -C(O)-N(C₁₋₄)alkyl)₂,
 -SO₂-(C₁₋₄)alkyl, -SO₂-NH₂, -SO₂-NH(C₁₋₄)alkyl, -SO₂-N(C₁₋₄)alkyl)₂, -C(N)-NH₂,
 25 -cycloalkyl-R⁸, -heterocyclyl-R⁹, -aryl-R⁸ or -heteroaryl-R⁹.

Another aspect of the present invention includes compounds of Formula (I) wherein R⁷ is 2 substituents independently selected from hydrogen or
 -(C₁₋₄)alkyl-R¹⁰.
 30

Aspects of the present invention include compounds of Formula (I)

wherein R^8 is up to 5 substituents independently selected from hydrogen, $-C_{1-4}alkyl$, $-C_{1-4}alkoxy$, $-NH_2$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)_2$, $-(C_{1-4}alkyl)-(halo)_{1-3}$, $-(C_{1-4}alkoxy)-(halo)_{1-3}$, $-(C_{1-4}alkyl)-OH$, cyano, halo, hydroxy or nitro.

5 Another aspect of the present invention includes compounds of Formula (I) wherein R^8 is hydrogen.

Aspects of the present invention include compounds of Formula (I) wherein R^9 is up to 5 substituents attached to a carbon or nitrogen atom
10 independently selected from hydrogen, $-C_{1-4}alkyl$, $-(C_{1-4}alkyl)-(halo)_{1-3}$ or $-(C_{1-4}alkyl)-OH$;

with the proviso that, when R^9 is attached to a carbon atom, R^9 is further selected from $-C_{1-4}alkoxy$, $-NH_2$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)_2$, $-(C_{1-4}alkoxy)-(halo)_{1-3}$, cyano, halo, hydroxy or nitro.

15

Another aspect of the present invention includes compounds of Formula (I) wherein R^9 is hydrogen.

Aspects of the present invention include compounds of Formula (I)
20 wherein R^2 is selected from $-C_{1-4}alkyl-R^6$, $-C_{2-4}alkenyl-R^6$, $-C_{2-4}alkynyl-R^6$, $-C(O)H$, $-C(O)-(C_{1-4}alkyl)-R^6$, $-C(O)-NH_2$, $-C(O)-NH(C_{1-4}alkyl)$, $-C(O)-N(C_{1-4}alkyl)_2$, $-C(O)-NH(aryl)$, $-C(O)-cycloalkyl$, $-C(O)-heterocyclyl$, $-C(O)-aryl$, $-C(O)-heteroaryl$, $-CO_2H$, $-C(O)-O-(C_{1-4}alkyl)-R^6$, $-C(O)-O-aryl$, $-SO_2-(C_{1-4}alkyl)-R^6$, $-SO_2-aryl$, $-cycloalkyl$, $-heterocyclyl$ (attached to the indole
25 nitrogen atom via a ring carbon atom), $-aryl$ or $-heteroaryl$ (attached to the indole nitrogen atom via a ring carbon atom).

Another aspect of the present invention includes compounds of Formula (I) wherein R^2 is selected from $-C_{1-4}alkyl-R^6$ and heteroaryl (attached to the
30 indole nitrogen atom via a ring carbon atom).

Aspects of the present invention include compounds of Formula (I) wherein R^3 is up to 4 substituents attached to a carbon atom independently selected from hydrogen, $-C_{1-4}alkyl-R^{10}$, $-C_{2-4}alkenyl-R^{10}$, $-C_{2-4}alkynyl-R^{10}$, $-C_{1-4}alkoxy-R^{10}$, $-C(O)H$, $-C(O)-(C_{1-4}alkyl)-R^{10}$, $-C(O)-NH_2$, $-C(O)-NH(C_{1-4}alkyl)$,
 5 $-C(O)-N(C_{1-4}alkyl)_2$, $-C(O)-cycloalkyl$, $-C(O)-heterocyclyl$, $-C(O)-aryl$, $-C(O)-heteroaryl$, $-C(NH)-NH_2$, $-CO_2H$, $-C(O)-O-(C_{1-4}alkyl)-R^{10}$, $-C(O)-O-aryl$, $-SO_2-(C_{1-4}alkyl)-R^{10}$, $-SO_2-aryl$, $-N-R^7$, cyano, halogen, hydroxy, nitro, $-cycloalkyl$, $-heterocyclyl$, $-aryl$ or $-heteroaryl$.

10 Another aspect of the present invention includes compounds of Formula (I) wherein R^3 is hydrogen.

Aspects of the present invention include compounds of Formula (I) wherein R^4 is up to 4 substituents attached to a carbon atom independently
 15 selected from hydrogen, $-C_{1-4}alkyl-R^{10}$, $-C_{2-4}alkenyl-R^{10}$, $-C_{2-4}alkynyl-R^{10}$, $-C_{1-4}alkoxy-R^{10}$, $-C(O)H$, $-C(O)-(C_{1-4}alkyl)-R^{10}$, $-C(O)-NH_2$, $-C(O)-NH(C_{1-4}alkyl)$, $-C(O)-N(C_{1-4}alkyl)_2$, $-C(O)-cycloalkyl$, $-C(O)-heterocyclyl$, $-C(O)-aryl$, $-C(O)-heteroaryl$, $-C(NH)-NH_2$, $-CO_2H$, $-C(O)-O-(C_{1-4}alkyl)-R^{10}$, $-C(O)-O-aryl$, $-SH$, $-S-(C_{1-4}alkyl)-R^{10}$, $-SO_2-(C_{1-4}alkyl)-R^{10}$, $-SO_2-aryl$, $-SO_2-NH_2$,
 20 $-SO_2-NH(C_{1-4}alkyl)$, $-SO_2-N(C_{1-4}alkyl)_2$, $-N-R^7$, cyano, halogen, hydroxy, nitro, $-cycloalkyl$, $-heterocyclyl$, $-aryl$ or $-heteroaryl$.

Another aspect of the present invention includes compounds of Formula (I) wherein R^4 is hydrogen.
 25


Aspects of the present invention include compounds of Formula (I) wherein R^{10} is 1 to 2 substituents independently selected from hydrogen, $-C_{1-4}alkoxy$, $-NH_2$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)_2$, cyano, $(halo)_{1-3}$, hydroxy, nitro or oxo.

30

Another aspect of the present invention includes compounds of Formula

(I) wherein R¹⁰ is hydrogen.

Exemplified compounds of Formula (I) include compounds selected from Formula (Ia):



Formula (Ia)

5 wherein R¹ and R² are selected from

Cpd	R ¹	R ²
1	3-pyridinyl	-(CH ₂) ₂ -OH;
2	5-pyrimidinyl	-(CH ₂) ₂ -OH;
3	3-quinolinyl	-(CH ₂) ₂ -OH;
4	3-pyridinyl	-(CH ₂) ₃ -OH;
5	3-benzo(<i>b</i>)thienyl	-(CH ₂) ₃ -NMe ₂ ;
6	phenyl	-(CH ₂) ₃ -NMe ₂ ;
7	5-pyrimidinyl	-CH ₃ ;
8	3-pyridinyl	-CH ₃ ;
9	3-pyridinyl	-(CH ₂) ₂ -tetrazol-2-yl;
10	3-pyridinyl	-(CH ₂) ₂ -tetrazol-1-yl;
11	3-pyridinyl	3-pyrimidinyl

and pharmaceutically acceptable salts thereof.

The compounds of the present invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." FDA approved pharmaceutically acceptable salt forms (*Ref.*

International J. Pharm. **1986**, 33, 201-217; *J. Pharm. Sci.*, **1977**, Jan, 66(1), p1)

include pharmaceutically acceptable acidic/anionic or basic/cationic salts.

Pharmaceutically acceptable acidic/anionic salts include, and are not limited to

acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium

5 edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate,

edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate,

glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide,

hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate,

malate, maleate, mandelate, mesylate, methylbromide, methylnitrate,

10 methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate,

phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate,

succinate, sulfate, tannate, tartrate, teoclate, tosylate and triethiodide.

Pharmaceutically acceptable basic/cationic salts include, and are not limited to

aluminum, benzathine, calcium, chloroprocaine, choline, diethanolamine,

15 ethylenediamine, lithium, magnesium, meglumine, potassium, procaine,

sodium and zinc. Other salts may, however, be useful in the preparation of

compounds according to this invention or of their pharmaceutically acceptable

salts. Organic or inorganic acids also include, and are not limited to,

hydroiodic, perchloric, sulfuric, phosphoric, propionic, glycolic,

20 methanesulfonic, hydroxyethanesulfonic, oxalic, 2-naphthalenesulfonic,

p-toluenesulfonic, cyclohexanesulfamic, saccharinic or trifluoroacetic acid.

The present invention includes within its scope prodrugs of the

compounds of this invention. In general, such prodrugs will be functional

25 derivatives of the compounds which are readily convertible *in vivo* into the

required compound. Thus, in the methods of treatment of the present

invention, the term "administering" shall encompass the treatment of the

various disorders described with the compound specifically disclosed or with a

compound which may not be specifically disclosed, but which converts to the

30 specified compound *in vivo* after administration to the subject. Conventional

procedures for the selection and preparation of suitable prodrug derivatives are

described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Where the compounds according to this invention have at least one
5 chiral center, they may accordingly exist as enantiomers. Where the
compounds possess two or more chiral centers, they may additionally exist as
diastereomers. Where the processes for the preparation of the compounds
according to the invention give rise to mixture of stereoisomers, these isomers
may be separated by conventional techniques such as preparative
10 chromatography. The compounds may be prepared in racemic form or
individual enantiomers may be prepared by standard techniques known to
those skilled in the art, for example, by enantiospecific synthesis or resolution,
formation of diastereomeric pairs by salt formation with an optically active acid,
followed by fractional crystallization and regeneration of the free base. The
15 compounds may also be resolved by formation of diastereomeric esters or
amides, followed by chromatographic separation and removal of the chiral
auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC
column. It is to be understood that all such isomers and mixtures thereof are
encompassed within the scope of the present invention.

20

During any of the processes for preparation of the compounds of the
present invention, it may be necessary and/or desirable to protect sensitive or
reactive groups on any of the molecules concerned. This may be achieved by
means of conventional protecting groups, such as those described in
25 Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press,
1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic
Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed
at a convenient subsequent stage using methods known in the art.

30 Furthermore, some of the crystalline forms for the compounds may exist
as polymorphs and as such are intended to be included in the present

invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.

5 Unless specified otherwise, the term "alkyl" refers to a saturated straight or branched chain consisting solely of 1-8 hydrogen substituted carbon atoms; preferably, 1-6 hydrogen substituted carbon atoms; and, most preferably, 1-4 hydrogen substituted carbon atoms. The term "alkenyl" refers to a partially
10 unsaturated straight or branched chain consisting solely of 2-8 hydrogen substituted carbon atoms that contains at least one double bond. The term "alkynyl" refers to a partially unsaturated straight or branched chain consisting solely of 2-8 hydrogen substituted carbon atoms that contains at least one
15 triple bond. The term "alkoxy" refers to –O-alkyl, where alkyl is as defined *supra*. The term "hydroxyalkyl" refers to radicals wherein the alkyl chain terminates with a hydroxy radical of the formula HO-alkyl, where alkyl is as
previously defined. Alkyl, alkenyl and alkynyl chains are optionally substituted within the alkyl chain or on a terminal carbon atom.

 The term "cycloalkyl" refers to a saturated or partially unsaturated
20 monocyclic alkyl ring consisting of 3-8 hydrogen substituted carbon atoms or a saturated or partially unsaturated bicyclic ring consisting of 9 or 10 hydrogen substituted carbon atoms. Examples include, and are not limited to, cyclopropyl, cyclopentyl, cyclopentenyl (containing one double bond), cyclopentynyl (containing one triple bond), cyclohexyl, cyclohexenyl (containing
25 at least one double bond), cyclohexynyl (containing at least one triple bond), cycloheptenyl (containing at least one double bond) or cycloheptynyl (containing at least one triple bond).

 The term "heterocyclyl" as used herein refers to an unsubstituted or substituted
30 stable three to seven membered monocyclic saturated or partially unsaturated ring system which consists of carbon atoms and from one to three heteroatoms

selected from N, O or S, or a stable eight to eleven membered bicyclic saturated or partially saturated ring system which consists of carbon atoms and from one to four heteroatoms selected from N, O, or S. In either the monocyclic or bicyclic rings the nitrogen or sulfur heteroatoms may optionally
5 be oxidized, and the nitrogen heteroatom may optionally be quaternized. Preferred are saturated or partially unsaturated rings having five or six members of which at least one member is a N, O or S atom and which optionally contains one additional N, O or S atoms; saturated or partially unsaturated bicyclic rings having nine or ten members of which at least one
10 member is a N, O or S atom and which optionally contains one or two additional N, O or S atoms; wherein said nine or ten membered bicyclic rings may have one aromatic ring and one nonaromatic ring. In another embodiment of this invention the previously defined heterocyclyl have as the additional heteroatom N, wherein at most two nitrogens atoms are adjacent.
15 Examples include, and are not limited to, aziridinyl, azetidiny, pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, imidazoliny, imidazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolidinyl, piperidinyl, morpholinyl or piperazinyl.

The term "aryl" refers to an aromatic monocyclic ring containing carbon
20 and hydrogen, such as a carbon ring containing 6 carbon atom with hydrogen atoms substituted thereon, an aromatic bicyclic ring system containing 10 carbon atoms with hydrogen substituted thereon or an aromatic tricyclic ring system containing 14 carbon atoms with hydrogen atoms substituted thereon. Also included within the scope of the definition of aryl are bicyclic and tricyclic
25 ring systems (containing carbon and hydrogen) wherein only one of the rings is aromatic such as tetrahydronaphthalene and indane. The hydrogen atoms on the monocyclic, bicyclic and tricyclic rings may be replaced with other groups or substituents as indicated. Examples include, and are not limited to, phenyl, naphthalenyl or anthracenyl.


30

The term "heteroaryl" as used herein represents an unsubstituted or

substituted stable five or six membered monocyclic aromatic ring system or an unsubstituted or substituted stable nine or ten membered benzo-fused heteroaromatic ring system (wherein both rings of the benzo-fused system are aromatic) or bicyclic heteroaromatic ring system and unsubstituted or substituted stable twelve to fourteen membered tricyclic ring systems which consists of carbon atoms and from one to four heteroatoms selected from N, O or S, and wherein the nitrogen heteroatom of any of these heteroaryls may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Preferred heteroaryl are aromatic monocyclic rings containing five members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; an aromatic monocyclic ring having six members of which one, two or three members are a N atoms; an aromatic bicyclic ring having nine members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; an aromatic bicyclic ring having ten members of which of which one, two, three or four members are N atoms; or, an aromatic tricyclic ring system containing 13 members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms. In another embodiment of this invention, the previously defined heteroaryls have as the additional heteroatom N, wherein at most four nitrogens atoms are adjacent. Examples include, and are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, benzo(*b*)thienyl, quinoliny, isoquinoliny or quinazoliny.

Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., aralkyl, alkylamino) it shall be interpreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms (e.g., C₁-C₆) shall refer independently to the number of carbon atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

Under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. Thus, for example, a "phenylC₁₋₆alkylamidoC₁₋₆alkyl" substituent refers to a group of the formula:



A substituent's point of attachment may also be indicated by a dashed line to indicate the point(s) of attachment, followed by the adjacent functionality and ending with the terminal functionality such as, for example, -(C₁₋₆)alkyl-NH-(C₁₋₆)alkyl-phenyl.

It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.

An embodiment of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above. Illustrative of the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. Another illustration of the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier. Further illustrative of the present invention are pharmaceutical compositions comprising one or more compounds of this invention in association with a

pharmaceutically acceptable carrier.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well
5 as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

The compounds of the present invention are selective kinase or dual-kinase inhibitors useful in a method for treating or ameliorating a kinase or
10 dual-kinase mediated disorder. In particular, the kinase is selected from protein kinase C or glycogen synthase kinase-3. More particularly, the kinase is selected from protein kinase C α , protein kinase C β -I, protein kinase C β -II protein kinase C γ or glycogen synthase kinase-3 β .

15 *Protein Kinase C Isoforms*

Protein kinase C is known to play a key role in intracellular signal transduction (cell-cell signaling), gene expression and in the control of cell differentiation and growth. The PKC family is composed of twelve isoforms that are further classified into 3 subfamilies: the calcium dependent classical
20 PKC isoforms alpha (α), beta-I (β -I), beta-II (β -II) and gamma (γ); the calcium independent PKC isoforms delta (δ), epsilon (ϵ), eta (η), theta (θ) and mu (μ); and, the atypical PKC isoforms zeta (ζ), lambda (λ) and iota (ι).

Certain disease states tend to be associated with elevation of particular
25 PKC isoforms. The PKC isoforms exhibit distinct tissue distribution, subcellular localization and activation-dependent cofactors. For example, the α and β isoforms of PKC are selectively induced in vascular cells stimulated with agonists such as vascular endothelial growth factor (VEGF) (P. Xia, et al., *J. Clin. Invest.*, **1996**, 98, 2018) and have been implicated in cellular growth,
30 differentiation, and vascular permeability (H. Ishii, et al., *J. Mol. Med.*, **1998**, 76, 21). The elevated blood glucose levels found in diabetes leads to an isoform-

specific elevation of the β -II isoform in vascular tissues (Inoguchi, et al., *Proc. Natl. Acad. Sci. USA*, **1992**, 89, 11059-11065). A diabetes-linked elevation of the β isoform in human platelets has been correlated with their altered response to agonists (Bastyr III, E. J. and Lu, J., *Diabetes*, **1993**, 42, (Suppl. 1) 5 97A). The human vitamin D receptor has been shown to be selectively phosphorylated by PKC β . This phosphorylation has been linked to alterations in the functioning of the receptor (Hsieh, et al., *Proc. Natl. Acad. Sci. USA*, **1991**, 88, 9315-9319; Hsieh, et al., *J. Biol. Chem.*, **1993**, 268, 15118-15126). In addition, the work has shown that the β -II isoform is responsible for 10 erythroleukemia cell proliferation while the α isoform is involved in megakaryocyte differentiation in these same cells (Murray, et al., *J. Biol. Chem.*, **1993**, 268, 15847-15853).

Cardiovascular Diseases

15 PKC activity plays an important role in cardiovascular diseases. Increased PKC activity in the vasculature has been shown to cause increased vasoconstriction and hypertension (Bilder, G. E., et al., *J. Pharmacol. Exp. Ther.*, **1990**, 252, 526-530). PKC inhibitors block agonist-induced smooth muscle cell proliferation (Matsumoto, H. and Sasaki, Y., *Biochem. Biophys. Res. Commun.*, **1989**, 158, 105-109). PKC β triggers events leading to 20 induction of Egr-1 (Early Growth Factor-1) and tissue factor under hypoxic conditions (as part of the oxygen deprivation-mediated pathway for triggering procoagulant events) (Yan, S-F, et al., *J. Biol. Chem.*, **2000**, 275, 16, 11921-11928). PKC β is suggested as a mediator for production of PAI-1 25 (Plaminogen Activator Inhibitor-1) and is implicated in the development of thrombosis and atherosclerosis (Ren, S, et al., *Am. J. Physiol.*, **2000**, 278, (4, Pt. 1), E656-E662). PKC inhibitors are useful in treating cardiovascular ischemia and improving cardiac function following ischemia (Muid, R. E., et al., *FEBS Lett.*, **1990**, 293, 169-172; Sonoki, H. et al., *Kokyu-To Junkan*, **1989**, 37, 30 669-674). Elevated PKC levels have been correlated with an increased

platelet function response to agonists (Bastyr III, E. J. and Lu, J., *Diabetes*, **1993**, 42, (Suppl. 1) 97A). PKC has been implicated in the biochemical pathway in the platelet-activating factor (PAF) modulation of microvascular permeability (Kobayashi, et al., *Amer. Phys. Soc.*, **1994**, H1214- H1220). PKC inhibitors affect agonist-induced aggregation in platelets (Toullec, D., et al., *J. Biol. Chem.*, **1991**, 266, 15771-15781). Accordingly, PKC inhibitors may be indicated for use in treating cardiovascular disease, ischemia, thrombotic conditions, atherosclerosis and restenosis.

10 Diabetes

Excessive activity of PKC has been linked to insulin signaling defects and therefore to the insulin resistance seen in Type II diabetes (Karasik, A., et al., *J. Biol. Chem.*, **1990**, 265, 10226-10231; Chen, K. S., et al., *Trans. Assoc. Am. Physicians*, **1991**, 104, 206-212; Chin, J. E., et al., *J. Biol. Chem.*, **1993**, 268, 6338-6347).

Diabetes-Associated Disorders

Studies have demonstrated an increase in PKC activity in tissues known to be susceptible to diabetic complications when exposed to hyperglycemic conditions (Lee, T-S., et al., *J. Clin. Invest.*, **1989**, 83, 90-94; Lee, T-S., et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 5141-5145; Craven, P. A. and DeRubertis, F. R., *J. Clin. Invest.*, **1989**, 87, 1667-1675; Wolf, B. A., et al., *J. Clin. Invest.*, **1991**, 87, 31- 38; Tesfamariam, B., et al., *J. Clin. Invest.*, **1991**, 87, 1643-1648). For example, activation of the PKC- β -II isoform plays an important role in diabetic vascular complications such as retinopathy (Ishii, H., et al., *Science*, **1996**, 272, 728-731) and PKC β has been implicated in development of the cardiac hypertrophy associated with heart failure (X. Gu, et al., *Circ. Res.*, **1994**, 75, 926; R. H. Strasser, et al., *Circulation*, **1996**, 94, 1551). Overexpression of cardiac PKC β II in transgenic mice caused cardiomyopathy involving hypertrophy, fibrosis and decreased left ventricular function (H.

Wakasaki, et al., *Proc. Natl. Acad. Sci. USA*, **1997**, 94, 9320).

Inflammatory Diseases

PKC inhibitors block inflammatory responses such as the neutrophil
5 oxidative burst, CD3 down-regulation in T-lymphocytes and phorbol-induced
paw edema (Twoemy, B., et al., *Biochem. Biophys. Res. Commun.*, **1990**, 171,
1087-1092; Mulqueen, M. J., et al. *Agents Actions*, **1992**, 37, 85-89). PKC β
has an essential role in the degranulation of bone marrow-derived mast cells,
thus affecting cell capacity to produce IL-6 (Interleukin-6) (Nechushtan, H., et
10 al., *Blood*, **2000** (March), 95, 5, 1752-1757). PKC plays a role in enhanced
ASM (Airway Smooth Muscle) cell growth in rat models of two potential risks for
asthma: hyperresponsiveness to contractile agonists and to growth stimuli
(Ren, S, et al., *Am. J. Physiol.*, **2000**, 278, (4, Pt. 1), E656-E662). PKC β -1
overexpression augments an increase in endothelial permeability, suggesting
15 an important function in the regulation of the endothelial barrier (Nagpala, P.G.,
et al., *J. Cell Physiol.*, **1996**, 2, 249-55). PKC β mediates activation of
neutrophil NADPH oxidase by PMA and by stimulation of Fc γ receptors in
neutrophils (Dekker, L.V., et al., *Biochem. J.*, **2000**, 347, 285-289). Thus, PKC
inhibitors may be indicated for use in treating inflammation and asthma.

20

Immunological Disorders

PKC may be useful in treating or ameliorating certain immunological
disorders. While one study suggests that HCMV (Human Cytomegalovirus)
inhibition is not correlated with PKC inhibition (Slater, M.J., et al., *Biorg. & Med.*
25 *Chem.*, **1999**, 7, 1067-1074), another study showed that the PKC signal
transduction pathway synergistically interacted with the cAMP-dependent PKA
pathway to activate or increase HIV-1 transcription and viral replication and
was abrogated with a PKC inhibitor (Rabbi, M.F., et al., *Virology*, **1998** (June
5), 245, 2, 257-69). Therefore, an immunological disorder may be treated or
30 ameliorated as a function of the affected underlying pathway's response to up-
or down-regulation of PKC.

PKC β deficiency also results in an immunodeficiency characterized by impaired humoral immune responses and a reduced B cell response, similar to X-linked immunodeficiency in mice, playing an important role in antigen
5 receptor-mediated signal transduction (Leitges, M., et al., *Science (Wash., D.C.)*, **1996**, 273, 5276, 788-789). Accordingly, transplant tissue rejection may be ameliorated or prevented by suppressing the immune response using a PKC β inhibitor.

10 *Dermatological Disorders*

Abnormal activity of PKC has been linked to dermatological disorders characterized by abnormal proliferation of keratinocytes, such as psoriasis (Horn, F., et al., *J. Invest. Dermatol.*, **1987**, 88, 220-222; Raynaud, F. and Evain-Brion, D., *Br. J. Dermatol.*, **1991**, 124, 542-546). PKC inhibitors have
15 been shown to inhibit keratinocyte proliferation in a dose-dependent manner (Hegemann, L., et al., *Arch. Dermatol. Res.*, **1991**, 283, 456-460; Bollag, W. B., et al., *J. Invest. Dermatol.*, **1993**, 100, 240-246).

Oncological Disorders

20 PKC activity has been associated with cell growth, tumor promotion and cancer (Rotenberg, S. A. and Weinstein, I. B., *Biochem. Mol. Aspects Sel. Cancer*, **1991**, 1, 25-73; Ahmad, et al., *Molecular Pharmacology*, **1993**, 43, 858-862); PKC inhibitors are known to be effective in preventing tumor growth in animals (Meyer, T., et al., *Int. J. Cancer*, **1989**, 43, 851-856; Akinagaka, S.,
25 et al., *Cancer Res.*, **1991**, 51, 4888-4892). PKC β -1 and β -2 expression in differentiated HD3 colon carcinoma cells blocked their differentiation, enabling them to proliferate in response to basic FGF (Fibroblast Growth Factor) like undifferentiated cells, increasing their growth rate and activating several MBP (Myelin-Basic Protein) kinases, including p57 MAP (Mitogen-Activated Protein)
30 kinase (Sauma, S., et al., *Cell Growth Differ.*, **1996**, 7, 5, 587-94). PKC α inhibitors, having an additive therapeutic effect in combination with other anti-

cancer agents, inhibited the growth of lymphocytic leukemia cells (Konig, A., et al., *Blood*, **1997**, 90, 10, Suppl. 1 Pt. 2). PKC inhibitors enhanced MMC (Mitomycin-C) induced apoptosis in a time-dependent fashion in a gastric cancer cell-line, potentially indicating use as agents for chemotherapy-induced apoptosis (Danso, D., et al., *Proc. Am. Assoc. Cancer Res.*, **1997**, 38, 88 Meet., 92). Therefore, PKC inhibitors may be indicated for use in ameliorating cell and tumor growth, in treating or ameliorating cancers (such as leukemia or colon cancer) and as adjuncts to chemotherapy.

PKC α (by enhancing cell migration) may mediate some proangiogenic effects of PKC activation while PKC δ may direct antiangiogenic effects of overall PKC activation (by inhibiting cell growth and proliferation) in capillary endothelial cells, thus regulating endothelial proliferation and angiogenesis (Harrington, E.O., et al., *J. Biol. Chem.*, **1997**, 272, 11, 7390-7397). PKC inhibitors inhibit cell growth and induce apoptosis in human glioblastoma cell lines, inhibit the growth of human astrocytoma xenografts and act as radiation sensitizers in glioblastoma cell lines (Begemann, M., et al., *Anticancer Res. (Greece)*, **1998** (Jul-Aug), 18, 4A, 2275-82). PKC inhibitors, in combination with other anti-cancer agents, are radiation and chemosensitizers useful in cancer therapy (Teicher, B.A., et al., *Proc. Am. Assoc. Cancer Res.*, **1998**, 39, 89 Meet., 384). PKC β inhibitors (by blocking the MAP kinase signal transduction pathways for VEGF (Vascular Endothelial Growth Factor) and bFGF (basic Fibrinogen Growth Factor) in endothelial cells), in a combination regimen with other anti-cancer agents, have an anti-angiogenic and antitumor effect in a human T98G glioblastoma multiforme xenograft model (Teicher, B.A., et al., *Clinical Cancer Research*, **2001** (March), 7, 634-640). Accordingly, PKC inhibitors may be indicated for use in ameliorating angiogenesis and in treating or ameliorating cancers (such as breast, brain, kidney, bladder, ovarian or colon cancers) and as adjuncts to chemotherapy and radiation therapy.

Central Nervous System Disorders

PKC activity plays a central role in the functioning of the central nervous system (CNS) (Huang, K. P., *Trends Neurosci.*, **1989**, 12, 425-432) and PKC is implicated in Alzheimer's disease (Shimohama, S., et al., *Neurology*, **1993**, 43, 1407-1413) and inhibitors have been shown to prevent the damage seen in focal and central ischemic brain injury and brain edema (Hara, H., et al., *J. Cereb. Blood Flow Metab.*, **1990**, 10, 646-653; Shibata, S., et al., *Brain Res.*, **1992**, 594, 290-294). Accordingly, PKC inhibitors may be indicated for use in treating Alzheimer's disease and in treating neurotraumatic and ischemia-related diseases.

10

The long-term increase in PKC γ (as a component of the phosphoinositide 2nd messenger system) and muscarinic acetylcholine receptor expression in an amygdala-kindled rat model has been associated with epilepsy, serving as a basis for the rat's permanent state of hyperexcitability (Beldhuis, H.J.A., et al., *Neuroscience*, **1993**, 55, 4, 965-73). Therefore, PKC inhibitors may be indicated for use in treating epilepsy.

15

The subcellular changes in content of the PKC γ and PKC β -II isoenzymes for animals in an *in-vivo* thermal hyperalgesia model suggests that peripheral nerve injury contributes to the development of persistent pain (Miletic, V., et al., *Neurosci. Lett.*, **2000**, 288, 3, 199-202). Mice lacking PKC γ display normal responses to acute pain stimuli, but almost completely fail to develop a neuropathic pain syndrome after partial sciatic nerve section (Chen, C., et al., *Science (Wash., D.C.)*, **1997**, 278, 5336, 279-283). PKC modulation may thus be indicated for use in treating chronic pain and neuropathic pain.

20

25

PKC has demonstrated a role in the pathology of conditions such as, but not limited to, cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders.

30

Glycogen Synthase Kinase-3

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase composed of two isoforms (α and β) which are encoded by distinct genes. GSK-3 is one of several protein kinases which phosphorylate glycogen synthase (GS) (Embi, et al., *Eur. J. Biochem*, **1980**, 107, 519-527). The α and β isoforms have a monomeric structure of 49 and 47kD respectively and are both found in mammalian cells. Both isoforms phosphorylate muscle glycogen synthase (Cross, et al., *Biochemical Journal*, **1994**, 303, 21-26) and these two isoforms show good homology between species (human and rabbit GSK-3 α are 96% identical).

Diabetes

Type II diabetes (or Non-Insulin Dependent Diabetes Mellitus, NIDDM) is a multifactorial disease. Hyperglycemia is due to insulin resistance in the liver, muscle and other tissues coupled with inadequate or defective secretion of insulin from pancreatic islets. Skeletal muscle is the major site for insulin-stimulated glucose uptake and in this tissue glucose removed from the circulation is either metabolised through glycolysis and the TCA (tricarboxylic acid) cycle or stored as glycogen. Muscle glycogen deposition plays the more important role in glucose homeostasis and Type II diabetic subjects have defective muscle glycogen storage. The stimulation of glycogen synthesis by insulin in skeletal muscle results from the dephosphorylation and activation of glycogen synthase (Villar-Palasi C. and Lerner J., *Biochim. Biophys. Acta*, **1960**, 39, 171-173, Parker P.J., et al., *Eur. J. Biochem.*, **1983**, 130, 227-234, and Cohen P., *Biochem. Soc. Trans.*, **1993**, 21, 555-567). The phosphorylation and dephosphorylation of GS are mediated by specific kinases and phosphatases. GSK-3 is responsible for phosphorylation and deactivation of GS, while glycogen bound protein phosphatase 1 (PP1G) dephosphorylates and activates GS. Insulin both inactivates GSK-3 and activates PP1G (Srivastava A.K. and Pandey S.K., *Mol. and Cellular Biochem.*, **1998**, 182, 135-141).

Studies suggest that an increase in GSK-3 activity might be important in Type II diabetic muscle (Chen, et al., *Diabetes*, **1994**, 43, 1234-1241).

Overexpression of GSK-3 β and constitutively active GSK-3 β (S9A, S9e)

- 5 mutants in HEK-293 cells resulted in suppression of glycogen synthase activity (Eldar-Finkelman, et al., *PNAS*, **1996**, 93, 10228-10233) and overexpression of GSK-3 β in CHO cells, expressing both insulin receptor and insulin receptor substrate 1 (IRS-1) resulted in impairment of insulin action (Eldar-Finkelman and Krebs, *PNAS*, **1997**, 94, 9660-9664). Recent evidence for the involvement
10 of elevated GSK-3 activity and the development of insulin resistance and Type II diabetes in adipose tissue has emerged from studies undertaken in diabetes and obesity prone C57BL/6J mice (Eldar-Finkelman, et al., *Diabetes*, **1999**, 48, 1662-1666).

15 *Dermatological Disorders*

The finding that transient β -catenin stabilization may play a role in hair development (Gat, et al., *Cell*, **1998**, 95, 605-614) suggests that GSK-3 inhibitors could also be used in the treatment of baldness.

20 *Inflammatory Diseases*

Studies on fibroblasts from the GSK-3 β knockout mouse indicate that inhibition of GSK-3 may be useful in treating inflammatory disorders or diseases through the negative regulation of NF κ B activity (Hoeflich K. P., et al., *Nature*, **2000**, 406, 86-90).

25

Central Nervous System Disorders

- In addition to modulation of glycogen synthase activity, GSK-3 also plays an important role in the CNS disorders. GSK-3 inhibitors may be of value as neuroprotectants in the treatment of acute stroke and other neurotraumatic
30 injuries (Pap and Cooper, *J. Biol. Chem.*, **1998**, 273, 19929-19932). Lithium, a low mM inhibitor of GSK-3, has been shown to protect cerebellar granule

neurons from death (D'Mello, et al., *Exp. Cell Res.*, **1994**, 211, 332-338) and chronic lithium treatment has demonstrable efficacy in the middle cerebral artery occlusion model of stroke in rodents (Nonaka and Chuang, *Neuroreport*, **1998**, 9(9), 2081-2084).

5

Tau and β -catenin, two known *in vivo* substrates of GSK-3, are of direct relevance in consideration of further aspects of the value of GSK-3 inhibitors in relation to treatment of chronic neurodegenerative conditions. Tau hyperphosphorylation is an early event in neurodegenerative conditions such as Alzheimer's disease and is postulated to promote microtubule disassembly. Lithium has been reported to reduce the phosphorylation of tau, enhance the binding of tau to microtubules and promote microtubule assembly through direct and reversible inhibition of GSK-3 (Hong M. et al *J. Biol. Chem.*, **1997**, 272(40), 25326-32). β -catenin is phosphorylated by GSK-3 as part of a tripartite axin protein complex resulting in β -catenin degradation (Ikeda, et al., *EMBO J.*, **1998**, 17, 1371-1384). Inhibition of GSK-3 activity is involved in the stabilization of catenin hence promotes β -catenin-LEF-1/TCF transcriptional activity (Eastman, Grosschedl, *Curr. Opin. Cell Biol.*, **1999**, 11, 233). Studies have also suggested that GSK-3 inhibitors may also be of value in treatment of schizophrenia (Cotter D., et al. *Neuroreport*, **1998**, 9, 1379-1383; Lijam N., et al., *Cell*, **1997**, 90, 895-905) and manic depression (Manji, et al., *J. Clin. Psychiatry*, **1999**, 60, (Suppl 2) 27-39 for review).

Accordingly, compounds found useful as GSK-3 inhibitors could have further therapeutic utility in the treatment of diabetes, dermatological disorders, inflammatory diseases and central nervous system disorders.

Embodiments of the method of the present invention include a method for treating or ameliorating a kinase or dual-kinase mediated disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an instant compound or pharmaceutical

composition thereof. The therapeutically effective amount of the compounds of Formula (I) exemplified in such a method is from about 0.001 mg/kg/day to about 300 mg/kg/day.

5 Embodiments of the present invention include the use of a compound of Formula (I) for the preparation of a medicament for treating or ameliorating a kinase or dual-kinase mediated disorder in a subject in need thereof.

10 In accordance with the methods of the present invention, an individual compound of the present invention or a pharmaceutical composition thereof can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted
15 accordingly.

 Embodiments of the present method include a compound or pharmaceutical composition thereof advantageously co-administered in combination with other agents for treating or ameliorating a kinase or dual-
20 kinase mediated disorder. For example, in the treatment of diabetes, especially Type II diabetes, a compound of Formula (I) or pharmaceutical composition thereof may be used in combination with other agents, especially insulin or antidiabetic agents including, but not limited to, insulin secretagogues (such as sulphonylureas), insulin sensitizers including, but not limited to,
25 glitazone insulin sensitizers (such as thiazolidinediones) or biguanides or α glucosidase inhibitors.

 The combination product comprises co-administration of a compound of Formula (I) or pharmaceutical composition thereof and an additional agent for
30 treating or ameliorating a kinase or dual-kinase mediated disorder, the sequential administration of a compound of Formula (I) or pharmaceutical

composition thereof and an additional agent for treating or ameliorating a kinase or dual-kinase mediated disorder, administration of a pharmaceutical composition containing a compound of Formula (I) or pharmaceutical composition thereof and an additional agent for treating or ameliorating a
5 kinase or dual-kinase mediated disorder or the essentially simultaneous administration of a separate pharmaceutical composition containing a compound of Formula (I) or pharmaceutical composition thereof and a separate pharmaceutical composition containing an additional agent for treating or ameliorating a kinase or dual-kinase mediated disorder.

10

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

15

The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

20

The ubiquitous nature of the PKC and GSK isoforms and their important roles in physiology provide incentive to produce highly selective PKC and GSK inhibitors. Given the evidence demonstrating linkage of certain isoforms to disease states, it is reasonable to assume that inhibitory compounds that are
25 selective to one or two PKC isoforms or to a GSK isoform relative to the other PKC and GSK isoforms and other protein kinases are superior therapeutic agents. Such compounds should demonstrate greater efficacy and lower toxicity by virtue of their specificity. Accordingly, it will be appreciated by one skilled in the art that a compound of Formula (I) is therapeutically effective for
30 certain kinase or dual-kinase mediated disorders based on the modulation of the disorder by selective kinase or dual-kinase inhibition. The usefulness of a

compound of Formula (I) as a selective kinase or dual-kinase inhibitor can be determined according to the methods disclosed herein and the scope of such use includes use in one or more kinase or dual-kinase mediated disorders.

5 Therefore, the term “kinase or dual-kinase mediated disorders” as used herein, includes, and is not limited to, cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and CNS disorders.

10 Cardiovascular diseases include, and are not limited to, acute stroke, heart failure, cardiovascular ischemia, thrombosis, atherosclerosis, hypertension, restenosis, retinopathy of prematurity or age-related macular degeneration. Diabetes includes insulin dependent diabetes or Type II non-insulin dependent diabetes mellitus. Diabetes-associated disorders include,
15 and are not limited to, impaired glucose tolerance, diabetic retinopathy, proliferative retinopathy, retinal vein occlusion, macular edema, cardiomyopathy, nephropathy or neuropathy. Inflammatory diseases include, and are not limited to, vascular permeability, inflammation, asthma, rheumatoid arthritis or osteoarthritis. Immunological disorders include, and are not limited
20 to, transplant tissue rejection, HIV-1 or immunological disorders treated or ameliorated by PKC modulation. Dermatological disorders include, and are not limited to, psoriasis, hair loss or baldness. Oncological disorders include, and are not limited to, cancer or tumor growth (such as breast, brain, kidney, bladder, ovarian or colon cancer or leukemia), proliferative angiopathy and
25 angiogenesis; and, includes use for compounds of Formula (I) as an adjunct to chemotherapy and radiation therapy. CNS disorders include, and are not limited to, chronic pain, neuropathic pain, epilepsy, chronic neurodegenerative conditions (such as dementia or Alzheimer's disease), mood disorders (such as schizophrenia), manic depression or neurotraumatic, cognitive decline and
30 ischemia-related diseases {as a result of head trauma (from acute ischemic stroke, injury or surgery) or transient ischemic stroke (from coronary bypass

surgery or other transient ischemic conditions}}.

A compound may be administered to a subject in need of treatment by any conventional route of administration including, but not limited to oral, nasal, sublingual, ocular, transdermal, rectal, vaginal and parenteral (i.e. subcutaneous, intramuscular, intradermal, intravenous etc.).

To prepare the pharmaceutical compositions of this invention, one or more compounds of Formula (I) or salt thereof as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral). Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.

Methods of formulating pharmaceutical compositions have been described in numerous publications such as Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1-3, edited by Lieberman, et al.; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis, et al.; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman, et al.; published by Marcel Dekker, Inc.

In preparing a pharmaceutical composition of the present invention in liquid dosage form for oral, topical and parenteral administration, any of the usual pharmaceutical media or excipients may be employed. Thus, for liquid dosage forms, such as suspensions (i.e. colloids, emulsions and dispersions) and solutions, suitable carriers and additives include but are not limited to

pharmaceutically acceptable wetting agents, dispersants, flocculation agents, thickeners, pH control agents (i.e. buffers), osmotic agents, coloring agents, flavors, fragrances, preservatives (i.e. to control microbial growth, etc.) and a liquid vehicle may be employed. Not all of the components listed above will be
5 required for each liquid dosage form.

In solid oral preparations such as, for example, powders, granules, capsules, caplets, gelcaps, pills and tablets (each including immediate release, timed release and sustained release formulations), suitable carriers and
10 additives include but are not limited to diluents, granulating agents, lubricants, binders, glidants, disintegrating agents and the like. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated, gelatin coated, film coated
15 or enteric coated by standard techniques.

The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described
20 above. The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.001 mg to about 300 mg (preferably, from about 0.01 mg to about 100 mg; and, more preferably, from about 0.1 mg to about 30 mg) and may be given at a dosage of from about 0.001 mg/kg/day to about 300
25 mg/kg/day (preferably, from about 0.01 mg/kg/day to about 100 mg/kg/day; and, more preferably, from about 0.1 mg/kg/day to about 30 mg/kg/day). Preferably, in the method for treating or ameliorating a kinase or dual-kinase mediated disorder described in the present invention and using any of the compounds as defined herein, the dosage form will contain a pharmaceutically
30 acceptable carrier containing between about 0.01 mg and 100 mg; and, more preferably, between about 5 mg and 50 mg of the compound; and, may be

constituted into any form suitable for the mode of administration selected. The dosages, however, may be varied depending upon the requirement of the subjects, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may
5 be employed.

Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, lozenges, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector
10 devices or suppositories for administration by oral, intranasal, sublingual, intraocular, transdermal, parenteral, rectal, vaginal, inhalation or insufflation means. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a
15 depot preparation for intramuscular injection.

For preparing solid pharmaceutical compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as diluents, binders, adhesives,
20 disintegrants, lubricants, antiadherents and glidants. Suitable diluents include, but are not limited to, starch (i.e. corn, wheat, or potato starch, which may be hydrolized), lactose (granulated, spray dried or anhydrous), sucrose, sucrose-based diluents (confectioner's sugar; sucrose plus about 7 to 10 weight percent invert sugar; sucrose plus about 3 weight percent modified dextrans; sucrose
25 plus invert sugar, about 4 weight percent invert sugar, about 0.1 to 0.2 weight percent cornstarch and magnesium stearate), dextrose, inositol, mannitol, sorbitol, microcrystalline cellulose (i.e. AVICEL[™] microcrystalline cellulose available from FMC Corp.), dicalcium phosphate, calcium sulfate dihydrate, calcium lactate trihydrate and the like. Suitable binders and adhesives include,
30 but are not limited to acacia gum, guar gum, tragacanth gum, sucrose, gelatin, glucose, starch, and cellulose (i.e. methylcellulose, sodium

carboxymethylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like), water soluble or dispersible binders (i.e. alginic acid and salts thereof, magnesium aluminum silicate, hydroxyethylcellulose (i.e. TYLOSE TM available from Hoechst Celanese), polyethylene glycol, polysaccharide acids, bentonites, polyvinylpyrrolidone, polymethacrylates and pregelatinized starch) and the like. Suitable disintegrants include, but are not limited to, starches (corn, potato, etc.), sodium starch glycolates, pregelatinized starches, clays (magnesium aluminum silicate), celluloses (such as crosslinked sodium carboxymethylcellulose and microcrystalline cellulose), alginates, pregelatinized starches (i.e. corn starch, etc.), gums (i.e. agar, guar, locust bean, karaya, pectin and tragacanth gum), cross-linked polyvinylpyrrolidone and the like. Suitable lubricants and antiadherents include, but are not limited to, stearates (magnesium, calcium and sodium), stearic acid, talc waxes, stearrowet, boric acid, sodium chloride, DL-leucine, carbowax 4000, carbowax 6000, sodium oleate, sodium benzoate, sodium acetate, sodium lauryl sulfate, magnesium lauryl sulfate and the like. Suitable glidants include, but are not limited to, talc, cornstarch, silica (i.e. CAB-O-SIL TM silica available from Cabot, SYLOID TM silica available from W.R. Grace/Davison and AEROSIL TM silica available from Degussa) and the like.

Sweeteners and flavorants may be added to chewable solid dosage forms to improve the palatability of the oral dosage form. Additionally, colorants and coatings may be added or applied to the solid dosage form for ease of identification of the drug or for aesthetic purposes. These carriers are formulated with the pharmaceutical active to provide an accurate, appropriate dose of the pharmaceutical active with a therapeutic release profile.

Generally these carriers are mixed with the pharmaceutical active to form a solid preformulation composition containing a homogeneous mixture of the pharmaceutical active of the present invention, or a pharmaceutically acceptable salt thereof. Generally the preformulation will be formed by one of three common methods: (a) wet granulation, (b) dry granulation and (c) dry

blending. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from about 0.1 mg to about 500 mg of the active ingredient of the present invention. The tablets or pills containing the novel compositions may also be formulated in multilayer tablets or pills to provide a sustained or provide dual-release products. For example, a dual release tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric materials such as shellac, cellulose acetate (i.e. cellulose acetate phthalate), polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, methacrylate and ethylacrylate copolymers, methacrylate and methyl methacrylate copolymers and the like. Sustained release tablets may also be made by film coating or wet granulation using slightly soluble or insoluble substances in solution (which for a wet granulation acts as the binding agents) or low melting solids a molten form (which in a wet granulation may incorporate the active ingredient). These materials include natural and synthetic polymers waxes, hydrogenated oils, fatty acids and alcohols (i.e. beeswax, carnauba wax, cetyl alcohol, cetylstearyl alcohol and the like), esters of fatty acids metallic soaps and other acceptable materials that can be used to granulate, coat, entrap or otherwise limit the solubility of an active ingredient to achieve a prolonged or sustained release product.

30

The liquid forms in which the novel compositions of the present

invention may be incorporated for administration orally or by injection include, but are not limited to aqueous solutions, suitably flavored syrups, aqueous or oil suspensions and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar

5 pharmaceutical vehicles. Suitable suspending agents for aqueous suspensions, include synthetic and natural gums such as, acacia, agar, alginate (i.e. propylene alginate, sodium alginate and the like), guar, karaya, locust bean, pectin, tragacanth and xanthan gum, cellulose such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose,

10 hydroxyethylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose and combinations thereof, synthetic polymers such as polyvinyl pyrrolidone, carbomer (i.e. carboxypolymethylene) and polyethylene glycol; clays such as bentonite, hectorite, attapulgit or sepiolite; and other pharmaceutically acceptable suspending agents such as lecithin, gelatin or the

15 like. Suitable surfactants include but are not limited to sodium docusate, sodium lauryl sulfate, polysorbate, octoxynol-9, nonoxynol-10, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxamer 188, polyoxamer 235 and combinations thereof. Suitable deflocculating or dispersing agent include pharmaceutical grade lecithins. Suitable flocculating agent include but

20 are not limited to simple neutral electrolytes (i.e. sodium chloride, potassium, chloride and the like), highly charged insoluble polymers and polyelectrolyte species, water soluble divalent or trivalent ions (i.e. calcium salts, alums or sulfates, citrates and phosphates (which can be used jointly in formulations as pH buffers and flocculating agents). Suitable preservatives include but are not

25 limited to parabens (i.e. methyl, ethyl, *n*-propyl and *n*-butyl), sorbic acid, thimerosal, quaternary ammonium salts, benzyl alcohol, benzoic acid, chlorhexidine gluconate, phenylethanol and the like. There are many liquid vehicles that may be used in liquid pharmaceutical dosage forms, however, the liquid vehicle that is used in a particular dosage form must be compatible with

30 the suspending agent(s). For example, nonpolar liquid vehicles such as fatty esters and oils liquid vehicles are best used with suspending agents such as

low HLB (Hydrophile-Lipophile Balance) surfactants, stearalkonium hectorite, water insoluble resins, water insoluble film forming polymers and the like.

Conversely, polar liquids such as water, alcohols, polyols and glycols are best used with suspending agents such as higher HLB surfactants, clays silicates,

5 gums, water soluble cellulosics, water soluble polymers and the like. For parenteral administration, sterile suspensions and solutions are desired. Liquid forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

10

Furthermore, compounds of the present invention can be administered in an intranasal dosage form via topical use of suitable intranasal vehicles or via transdermal skin patches, the composition of which are well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery

15 system, the administration of a therapeutic dose will, of course, be continuous rather than intermittent throughout the dosage regimen.

15

Compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large

20 unilamellar vesicles, multilamellar vesicles and the like. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, phosphatidylcholines and the like.

20

Compounds of the present invention may also be delivered by the use of

25 monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include, but are not limited to polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxy-ethylaspartamidephenol,

30 or polyethyl eneoxydepolylysine substituted with palmitoyl residue. Furthermore, the compounds of the present invention may be coupled to a class of

25

30

biodegradable polymers useful in achieving controlled release of a drug, for example, to homopolymers and copolymers (which means polymers containing two or more chemically distinguishable repeating units) of lactide (which includes lactic acid d-, l- and meso lactide), glycolide (including glycolic acid), ϵ -caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ -valerolactone, β -butyrolactone, γ -butyrolactone, ϵ -decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one (including its dimer 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels and blends thereof.

Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever treating or ameliorating a kinase or dual-kinase mediated disorder is required for a subject in need thereof; in particular, whenever treating or ameliorating a kinase disorder mediated by selective inhibition of a kinase selected from protein kinase C or glycogen synthase kinase-3 is required; and, whenever treating or ameliorating a kinase disorder mediated by dual inhibition of at least two kinases selected from protein kinase C and glycogen synthase kinase-3 is required; and, more particularly, whenever treating or ameliorating a kinase disorder mediated by selective inhibition of a kinase selected from protein kinase C α , protein kinase C β -I, protein kinase C β -II, protein kinase C γ or glycogen synthase kinase-3 β is required; and, whenever treating or ameliorating a kinase disorder mediated by dual inhibition of at least two kinases selected from protein kinase C α , protein kinase C β -I, protein kinase C β -II, protein kinase C γ or glycogen synthase kinase-3 β is required.

30

The daily dose of a pharmaceutical composition of the present invention

may be varied over a wide range from about 0.7 mg to about 21,000 mg per 70 kilogram (kg) adult human per day; preferably in the range of from about 7 mg to about 7,000 mg per adult human per day; and, more preferably, in the range of from about 7 mg to about 2,100 mg per adult human per day. For oral

5 administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. A therapeutically effective amount of the drug is ordinarily supplied at a dosage level of from about 0.001

10 mg/kg to about 300 mg/kg of body weight per day. Preferably, the range is from about 0.1 mg/kg to about 100 mg/kg of body weight per day; and, most preferably, from about 0.1 mg/kg to about 30 mg/kg of body weight per day. Advantageously, compounds of the present invention may be administered in a single daily dose or the total daily dosage may be administered in divided

15 doses of two, three or four times daily.

Optimal dosages to be administered may be readily determined by those skilled in the art and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement

20 of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level.

25 Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows:

ATP	=	adenosinetriphosphate
BSA	=	bovine serum albumin
DCM	=	dichloromethane
30 DMF	=	N, N-dimethylformamide
DMSO	=	dimethylsulfoxide
EGTA	=	ethylenebis(oxyethylenenitrilo)tetraacetic acid


h	=	hour
HEPES	=	4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
min	=	minute
rt	=	room temperature
5 TCA	=	trichloroacetic acid
THF	=	tetrahydrofuran
TFA	=	trifluoroacetic acid
TMSCHN ₂	=	trimethylsilyldiazomethane

10 General Synthetic Methods


Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.

The following schemes describe general synthetic methods whereby
intermediate and target compounds of the present invention may be prepared.
Additional representative compounds of the present invention can be
synthesized using the intermediates prepared in accordance with the schemes
and other materials, compounds and reagents known to those skilled in the art.

25 In Scheme AA, the substituted indole Compound **AA1** was arylated with an appropriately substituted aryl or heteroaryl halide and a base such as potassium carbonate and copper oxide in a dipolar aprotic solvent such as DMF to give Compound **AA2**. Compound **AA2** was acylated with oxalyl chloride in an aprotic solvent such as diethyl ether or DCM and quenched with
30 sodium methoxide to afford an intermediate glyoxylic ester Compound **AA3**.




The substituted indole amide Compound **AA4** was alkylated or arylated
 5 with an appropriately alkylating or arylating agent and a base such as
 potassium carbonate or sodium hydride (for alkylation) or potassium carbonate
 and copper oxide (for arylation) in a dipolar aprotic solvent such as DMF to
 give Compound **AA5**.



10

The ester Compound **AA3** was then reacted with the amide Compound
AA5 stirred in an aprotic solvent such as THF with ice bath cooling and a base
 such as potassium *tert*-butoxide or sodium hydride to give a target Compound
AA6.



15

Specific Synthetic Methods

Specific compounds which are representative of this invention were prepared

as per the following examples and reaction sequences; the examples and the diagrams depicting the reaction sequences are offered by way of illustration, to aid in the understanding of the invention and should not be construed to limit in any way the invention set forth in the claims which follow thereafter. The depicted intermediates may also be used in subsequent examples to produce additional compounds of the present invention. No attempt has been made to optimize the yields obtained in any of the reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.

10

All chemicals were obtained from commercial suppliers and used without further purification. ^1H and ^{13}C NMR spectra were recorded on a Bruker AC 300B (300 MHz proton) or a Bruker AM-400 (400 MHz proton) spectrometer with Me_4Si as an internal standard (s = singlet, d = doublet, t = triplet, br = broad). APCI-MS and ES-MS were recorded on a VG Platform II mass spectrometer; methane was used for chemical ionization, unless noted otherwise. Accurate mass measurements were obtained by using a VG ZAB 2-SE spectrometer in the FAB mode. TLC was performed with Whatman 250- μm silica gel plates. Preparative TLC was performed with Analtech 1000- μm silica gel GF plates. Flash column chromatography was conducted with flash column silica gel (40-63 μm) and column chromatography was conducted with standard silica gel. HPLC separations were carried out on three Waters PrepPak[®] Cartridges (25 x 100 mm, Bondapak[®] C18, 15-20 μm , 125 Å) connected in series; detection was at 254 nm on a Waters 486 UV detector. Analytical HPLC was carried out on a Supelcosil ABZ+PLUS column (5 cm x 2.1 mm), with detection at 254 nm on a Hewlett Packard 1100 UV detector. Microanalysis was performed by Robertson Microlit Laboratories, Inc.

30

Representative Chemical Abstracts Service (CAS) Index-like names for the compounds of the present invention were derived using the ACD/LABS SOFTWARE[™] Index Name Pro Version 4.5 nomenclature software program

provided by Advanced Chemistry Development, Inc., Toronto, Ontario, Canada.

Example 1


5 3-[1-(2-hydroxyethyl)-1*H*-indol-3-yl]-4-[1-(3-pyridinyl)-1*H*-indol-3-yl]-1*H*-pyrrole-2,5-dione (Compound **1**)

Indole Compound **1a** (2.34 g, 20 mmol) and 3-bromopyridine (3.16 g, 20 mmol) were dissolved in DMF (10 mL) and potassium carbonate (2.76 g, 20 mmol). CuO (130 mg, 1.6 mmol) was added and the reaction was refluxed under
10 argon for 16 h. The mixture was cooled to rt and partitioned between DCM (100 mL) and water (100 mL). The organic layer was washed with water (3 X 50 mL) and brine (2 X 50 mL), then dried (Na₂SO₄) and evaporated *in vacuo* to a brown oil. The product was purified *via* flash column chromatography (ethyl acetate:hexane; 1:1) to give Compound **1b** (3.16 g, 81%) as a colorless oil.
15 The indole Compound **1b** (0.78 g, 4.0 mmol) in DCM (12 mL) was treated with oxalyl chloride (0.52 g, 4.1 mmol) with ice bath cooling and then stirred at ambient temperature for 16 h. The solution was cooled to -65 °C and sodium methoxide (0.46 g, 8.0 mmol) in methanol (10 mL) was added slowly; the reaction was stirred at ambient temperature for 1 h and then evaporated *in*
20 *vacuo* to a solid. The solid was extracted with chloroform (25 mL), filtered and the filtrate dried (K₂CO₃) and evaporated *in vacuo* to provide Compound **1c** (0.73 g, 65%) as a grey solid. ¹H NMR (CDCl₃) δ 8.88 (d, J = 2.3 Hz, 1H), 8.77 (dd, J = 4.7, 1.3 Hz, 1H), 8.60 (s, 1H), 8.54 (d, J = 7.1 Hz, 1H), 7.90 (m, 1H), 7.56 (m, 1H), 7.43 (m, 3H), 3.98 (s, 3H). ES-MS m/z 281 (MH⁺).

25 The indole Compound **1d** (5 g, 28.7 mmol) in DMF (40 mL) was cooled in an ice bath followed by addition of 60% NaH (0.76 g, 31.6 mmol). The mixture was stirred at room temperature for 30 min. Silyl-protected 2-bromo-1-ethanol Compound **1e** (7.55 g, 31.6 mmol) was added and the mixture was stirred at rt
30 for 8 h. Then water was added and extracted with EtOAc several times. The organic layers were combined and washed with brine, then dried (Na₂SO₄) and

evaporated *in vacuo* to provide an oil. The oil was purified by flash column chromatography (95:5:0.5; DCM: MeOH: NH₄OH) to give an amide Compound **1f** (9.22 g, 97%). ¹H NMR (CDCl₃) δ 7.69 (d, J = 7.8 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.30 (m, 3H), 5.78 (bd s, 1H), 5.66 (bd s, 1H), 4.34 (t, J = 5.5 Hz, 2H), 4.03 (t, J = 5.5 Hz, 2H), 3.84 (s, 2H), 0.94 (s, 9H), 0.01 (s, 6H). ES-MS m/z 333 (MH⁺).

The methyl ester **1c** (2.12 g, 6.37 mmol) and amide Compound **1f** (2.5 g, 8.92 mmol) were combined in dry THF (15 mL) under argon and cooled in an ice bath as 1M potassium t-butoxide in THF (31 mL, 31 mmol) was added with stirring over a 15 min period. After 40 min, the reaction was quenched in an ice bath while 12 N HCl (4 mL, 48 mmol) was slowly added. The mixture was stirred for 15 min at rt, made slightly basic by the addition of 3N NaOH and extracted with EtOAc. The organic layers were combined and washed with saturated NaHCO₃ and brine, then dried (Na₂SO₄) and evaporated *in vacuo* to give a crude solid. The solid was then purified by flash column chromatography (97:3:0.3; DCM: MeOH: NH₄OH) to afford Compound **1** (1.24 g, 44%) as a red flaky solid. Compound **1** was dissolved in excess dilute HCl, then frozen and lyophilized to give the hydrochloride salt. ¹H NMR (CD₃OD) δ 9.05 (s, 1H), 8.79 (m, 1H), 8.69 (m, 1H), 8.14 (m, 1H), 7.95 (s, 1H), 7.91 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 8.23 Hz, 1H), 7.20 (m, 2H), 7.07 (t, J = 7.6 Hz, 1H), 6.92 (t, J = 7.6 Hz, 1H), 6.81 (d, J = 7.9 Hz, 1H), 6.66 (t, J = 7.6 Hz, 1H), 4.33 (t, J = 5.4 Hz, 2H), 3.89 (t, J = 5.3 Hz, 2H). ES-MS m/z 449 (MH⁺). Anal. Calcd. for C₂₇H₂₀N₄O₃ · 0.98HCl · 0.89 H₂O: C, 64.83; H, 4.59; N, 11.2; Cl, 6.95; KF, 3.21. Found: C, 64.83; H, 4.45; N, 11.22; Cl, 7.13; KF, 3.29.



Using the procedure of Example 1 and the appropriate reagents and starting materials known to those skilled in the art, other compounds of the present invention may be prepared including, but not limited to:

Cpd	Name	MS m/z (MH ⁺)
2	3-[1-(2-hydroxyethyl)-1H-indol-3-yl]-4-[1-(5-pyrimidinyl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione	450
4	3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-[1-(3-pyridinyl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione	463
5	3-(1-benzo[b]thien-3-yl)-1H-indol-3-yl]-4-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione	545

6	3-[1-[3-(dimethylamino)propyl]-1 <i>H</i> -indol-3-yl]-4-(1-phenyl-1 <i>H</i> -indol-3-yl)-1 <i>H</i> -pyrrole-2,5-dione	489
7	3-(1-methyl-1 <i>H</i> -indol-3-yl)-4-[1-(5-pyrimidinyl)-1 <i>H</i> -indol-3-yl]-1 <i>H</i> -pyrrole-2,5-dione	420
8	3-(1-methyl-1 <i>H</i> -indol-3-yl)-4-[1-(3-pyridinyl)-1 <i>H</i> -indol-3-yl]-1 <i>H</i> -pyrrole-2,5-dione	419


Example 2

3-[1-(2-hydroxyethyl)-1*H*-indol-3-yl]-4-[1-(3-quinolinyl)-1*H*-indol-3-yl]-1*H*-pyrrole-2,5-dione (Compound 3)

- 5 Following the procedure for preparation of Compound 1 (Example 1), using 3-bromoquinoline in place of 3-bromopyridine, 1-(3-quinolinyl)-indol-3-yl glyoxylic methyl ester Compound 2a was prepared. ¹H NMR (CDCl₃) δ 9.15 (d, J = 2.3 Hz, 1H), 8.69 (s, 1H), 8.55 (d, J = 7.1 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.28 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.87 (m, 1H), 7.72 (m, 1H),
10 7.45 (m, 3H), 3.98 (s, 3H).

- The methyl ester Compound 2a (0.3 g, 0.97 mmol) and amide Compound 1f (0.2 g, 0.65 mmol) were combined in dry THF (5 mL) under argon and cooled in an ice bath as 1M potassium t-butoxide in THF (3.3 mL, 3.3 mmol) was
15 added with stirring over a 10 min period. After 40 min, the reaction was quenched in an ice bath while 12 N HCl (4 mL, 48 mmol) was slowly added. The mixture was stirred for 15 min at rt, made slightly basic by the addition of 3N NaOH and extracted with EtOAc. The organic layers were combined and washed with saturated NaHCO₃ and brine, then dried (Na₂SO₄) and
20 evaporated *in vacuo* to give a crude solid (0.55g). The solid was then purified by flash column chromatography (97:3:0.3; DCM: MeOH: NH₄OH) to afford Compound 3 (65 mg, 22%) as a red flaky solid. Compound 3 was dissolved in excess dilute HCl, then frozen and lyophilized to give the hydrochloride salt. ¹H NMR (CD₃OD) δ 9.29 (m, 1H), 8.93 (m, 1H), 8.25 (m, 2H), 8.09 (m, 1H),
25 7.96 (m, 3H), 7.66 (m, 1H), 7.49 (m, 1H), 7.25 (m, 2H), 7.12 (t, J = 7.2 Hz, 1H), 6.96 (t, J = 7.7 Hz, 1H), 6.86 (m, 1H), 6.73 (t, J = 7.6 Hz, 1H), 4.36 (t, J = 5.4

Hz, 2H), 3.92 (t, J = 5.4 Hz, 2 H). ES-MS m/z 499 (MH⁺). Anal. Calcd. for C₃₁H₂₂N₄O₃ · 0.57HCl · 0.99 H₂O: C, 69.32; H, 4.61; Cl, 3.77; N, 10.44; KF, 3.33. Found: C, 69.32; H, 4.49; N, 10.36; Cl, 3.93; KF, 3.22.



Example 3


5 3-[1-(3-pyridinyl)-1H-indol-3-yl]-4-[1-[2-(2H-tetrazol-2-yl)ethyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione (Compound **9**)

3-[1-(3-pyridinyl)-1H-indol-3-yl]-4-[1-[2-(1H-tetrazol-1-yl)ethyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione (Compound **10**)

Pyridine (0.16 g, 2.01 mmol) and methanesulfonic anhydride (0.23 g, 1.34 mmol) were added to a mixture of Compound **1** (0.3 g, 0.67 mmol) in THF (20 mL). The mixture was heated at 50 °C for 4h, and then cooled to rt. Another portion of THF (3 mL) was added, followed by 1N HCl (3 mL). The mixture was stirred for another 15 min, then extracted with EtOAc several times. The combined EtOAc layers were washed with water (2 x 20 mL) and saturated NaCl (20 mL), then dried (Na₂SO₄) and evaporated to obtain Compound **3a** (0.35 g, 100%) as a reddish solid. ES-MS m/z 527 (MH⁺).

Potassium carbonate (1g, 7.2 mmol), followed by DMF (20 mL), was added to a solution of 3% tetrazole in acetonitrile (20 mL, 6.77 mmol). The mixture was heated at 90 °C for 4h, then cooled to rt and Compound **3a** (0.4 g, 0.76 mmol)

in DMF (20 mL) was added dropwise. The mixture was then heated at 80 °C overnight. The solvent was evaporated and H₂O (20 mL) was added, then extracted with EtOAc. The organic layer was then dried (Na₂SO₄) and concentrated to give a crude solid. The solid was then purified by flash column chromatography (95:5:0.5; DCM: MeOH: NH₄OH) to afford Compound **9** (0.1 g, 26%) and Compound **10** (36 mg, 9.5 %) as orange solids. Compound **9** (free base): ¹H NMR (CDCl₃) δ 8.71 (d, J = 2.3 Hz, 1H), 8.65 (m, 1H), 8.49 (s, 1H), 7.78 (m, 2H), 7.48 (m, 3H), 7.17 (m, 4H), 6.98 (t, J = 7.1 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.78 (t, J = 7.4 Hz, 1H), 5.09 (t, J = 6.0 Hz, 2H), 4.82 (t, J = 6.0 Hz, 2H). ES-MS m/z 501 (MH⁺). Compound **10** was dissolved in excess dilute HCl, then frozen and lyophilized to give the hydrochloride salt: ¹H NMR (DMSO-d₆) δ 11.08 (s, 1H), 9.23 (s, 1H), 8.85 (m, 2H), 8.06 (m, 1H), 7.93 (s, 1H), 7.81 (m, 2H), 7.52 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.14 (m, 1H), 6.95 (m, 3 H), 6.64 (m, 2H), 4.96 (m, 2H), 4.84 (m, 2H). ES-MS m/z 501 (MH⁺).




Example 43-[1-(3-pyridinyl)-1*H*-indol-3-yl]-4-[1-(5-pyrimidinyl)-1*H*-indol-3-yl]-1*H*-pyrrole-2,5-dione (Compound **11**)

Indole amide (**1d**) (2.09 g, 12 mmol) and 5-bromopyrimidine (2.48 g, 15.6 mmol) were dissolved in DMF (12 mL), and potassium carbonate (1.82 g, 13.2 mmol) and CuO (477 mg, 6.0 mmol) were added and the reaction was stirred at 165 °C for 18 h. The volatiles were removed under vacuo and the residue was partitioned between CHCl₃ (300 mL) and water (150 mL). Two layers were separated and the aqueous layer was extracted with CHCl₃ (100 mL). The combined organic layers were washed with water, brine and then filtered through Celite to remove insolubles. The filtrate was evaporated under vacuo to ca. 30 mL of volume, to which were added EtOAc (50 mL) and hexane (20 mL). The mixture was cooled to 0 °C, and the resulting solid was collected by filtration to give 1.30 g of Compound **4a** as a light yellow solid. ¹H NMR (CD₃OD) δ 9.13 (s, 1 H), 9.10 (s, 2 H), 7.69 (d, *J* = 8.0 Hz, 1 H), 7.60 (d, *J* = 8.2 Hz, 1 H), 7.53 (s, 1 H), 7.30-7.22 (m, 2 H), 3.74 (s, 2 H). ES-MS *m/z* 253 (MH⁺).

The α-keto ester **1c** (78 mg, 0.28 mmol) and amide Compound **4a** (50 g, 0.2 mmol) were combined in dry THF (3 mL) under argon and cooled in an ice bath as 1M potassium *t*-butoxide in THF (0.8 mL, 0.8 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 40 min, then rt for 80 min. The mixture was cooled back to 0 °C while 12 N HCl (1 mL) was slowly added. After stirred at rt for 5 min, the mixture was diluted with H₂O (5 mL), basified with 3N NaOH, and extracted with EtOAc. The organic layers were combined and washed with brine, dried (Na₂SO₄) and evaporated *in vacuo* to give a crude solid. The crude product was purified by reverse-phase HPLC using a gradient of 10% to 90% acetonitrile/water (containing 0.2% TFA) to afford Compound **11** (32 mg) as a red-orange solid (TFA salt). ¹H NMR (DMSO-*d*₆) δ

9.26 (s, 1 H), 9.07 (s, 2 H), 8.74 (s, 1 H), 8.66 (d, $J = 3.6$ Hz, 1 H), 8.14 (s, 1 H), 8.08 (m, 1 H), 8.05 (s, 1 H), 7.66 (dd, $J = 4.7, 8.2$ Hz, 1 H), 7.61 (d, $J = 8.3$ Hz, 1 H), 7.53 (d, $J = 8.3$ Hz, 1 H), 7.20 (m, 2 H), 7.12 (s, 1 H), 7.09 (s, 1H), 6.96 (m, 2H). ES-MS m/z 483 (MH^+).

5



Example 5

As a specific embodiment of an oral composition, 100 mg of Compound **1** is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.

10

Biological Experimental Examples

The utility of the compounds to treat kinase or dual-kinase mediated disorders (in particular, kinases selected from protein kinase C and glycogen synthase kinase-3; and, more particularly, kinases selected from protein kinase C α , protein kinase C β -II, protein kinase C γ or glycogen synthase kinase-3 β) was

determined using the following procedures.

Example 1

Protein Kinase C Histone-Based Assay

Compounds were evaluated for PKC selectivity using histone III as the
 5 substrate. The PKC isoforms α , β -II or γ were added to a reaction mixture that
 contained 20 mM HEPES, (pH 7.4), 940 μ M CaCl_2 , 10 mM MgCl_2 , 1 mM
 EGTA. 100 μ g/mL phosphatidylserine, 20 μ g/mL diacylglycerol, 30 μ M ATP, 1
 μ Ci (^{33}P)ATP and 200 μ g/mL histone III. The reaction was incubated for 10
 min at 30°C. Reactions were terminated by TCA precipitation and spotting on
 10 Whatman P81 filters. Filters were washed in 75 mM phosphoric acid and the
 radioactivity quantified by liquid scintillation counting.

Table 1 shows the biological activity in the histone based assay as IC_{50}
 values (μ M) for representative compounds of the present invention.

15

Table 1

PKC Activity (IC_{50} μ M, Histone Based Assay)

Cpd	Beta II	Alpha	Gamma
1	0.006	0.064	0.274
2	0.015	0.228	0.429
3	0.023	0.457	0.784
6	0.023	0.058	---
9	0.054	0.910	4.954
10	0.123	1.010	4.569
11	0.060	3.037	1.436

The data presented in this table has an error of approximately within ± 30 percent.

Example 2

Glycogen Synthase Kinase-3 Assay

Compounds were tested for the ability to inhibit recombinant rabbit GSK-3 β

using the following protocol. The test compound was added to a reaction mixture containing Protein phosphatase inhibitor-2 (PPI-2) (Calbiochem) (45 ng), rabbit GSK-3 β (New England Biolabs) (0.75 units) and ^{33}P -ATP (1 μCi) in 50 mM Tris-HCl (pH 8.0), 10 mM MgCl_2 , 0.1% BSA, 1 mM DTT and 100 μM Sodium Vanadate. The mixture was reacted for 90 minutes at 30°C to allow phosphorylation of the PPI-2 protein and then the protein in the reaction was precipitated using 10 % TCA. The precipitated protein was collected on filter plates (MultiScreen-DV/Millipore), which were subsequently washed. Finally, the radioactivity was quantified using a TopCount Scintillation Counter (Packard). GSK-3 inhibitory compounds resulted in less phosphorylated PPI-2 and thus a lower radioactive signal in the precipitated protein. Staurosporine or Valproate, known inhibitors of GSK-3 β , were used as a positive control for screening.

Table 2 shows the biological activity in the GSK-3 β assay as IC_{50} values (μM) for representative compounds of the present invention.

Table 2
GSK-3 β Assay Activity (IC_{50} μM)

Cpd	GSK-3 β
1	0.025
2	0.008
3	0.031
4	0.024
5	53% @ 1 μM
7	0.030
8	0.100
9	0.007
10	0.017

Cpd	GSK-3 β
11	0.116

The results from the foregoing indicate that a compound of the present invention would be expected to be useful in treating or ameliorating a kinase or dual-kinase mediated disorder.


5

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the

10 following claims and their equivalents.

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



Formula (I)

5 wherein

R¹ is selected from the group consisting of a pyridinyl-R⁵, pyrimidinyl-R⁵, pyrazinyl-R⁵, furyl-R⁵, thienyl-R⁵, benzofuryl-R⁵, benzothienyl-R⁵, quinolinyl-R⁵ and isoquinolinyl-R⁵ ring attached to the indole nitrogen atom via a ring carbon atom;

10

R⁵ is up to 4 substituents independently selected from the group consisting of hydrogen, -(C₁-₈)alkyl-R⁶, -(C₂-₈)alkenyl-R⁶, -(C₂-₈)alkynyl-R⁶, -O-(C₁-₈)alkyl-R⁶, -O-C(O)H, -O-C(O)-(C₁-₈)alkyl-R⁶, -O-C(O)-NH₂, -O-C(O)-NH(C₁-₈alkyl), -O-C(O)-N(C₁-₈alkyl)₂, -C(O)H, -C(O)-(C₁-₈)alkyl-R⁶, -CO₂H, -C(O)-O-(C₁-₈)alkyl-R⁶, -C(O)-NH₂, -C(NH)-NH₂, -C(O)-NH(C₁-₈alkyl), -C(O)-N(C₁-₈alkyl)₂, -SH, -S-(C₁-₈)alkyl-R⁶; -SO₂-(C₁-₈)alkyl-R⁶, -SO₂-NH₂, -SO₂-NH(C₁-₈alkyl), -SO₂-N(C₁-₈alkyl)₂, -N-R⁷, cyano, halo, hydroxy, nitro, -cycloalkyl-R⁸, -heterocyclyl-R⁹, -aryl-R⁸ and -heteroaryl-R⁹;

15

20 R⁶ is up to 2 substituents independently selected from the group consisting of hydrogen, -O-(C₁-₈)alkyl, -O-(C₁-₈)alkyl-OH, -O-(C₁-₈)alkyl-NH₂, -O-(C₁-₈)alkyl-NH(C₁-₈alkyl), -O-(C₁-₈)alkyl-N(C₁-₈alkyl)₂, -C(O)H, -C(O)-(C₁-₈)alkyl, -CO₂H, -C(O)-O-(C₁-₈)alkyl, -C(O)-NH₂,

-C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -S-(C₁₋₈alkyl), -SO₂-(C₁₋₈alkyl),
 -SO₂-NH₂, -SO₂-NH(C₁₋₈alkyl), -SO₂-N(C₁₋₈alkyl)₂, -N-R⁷, cyano, (halo)₁₋₃,
 hydroxy, nitro, oxo, -cycloalkyl, -heterocyclyl, -aryl and -heteroaryl;

- 5 R⁷ is 2 substituents independently selected from the group consisting of
 hydrogen, -(C₁₋₈alkyl)-R¹⁰, -(C₂₋₈alkenyl)-R¹⁰, -(C₂₋₈alkynyl)-R¹⁰,
 -C(O)-(C₁₋₈alkyl)-R¹⁰, -C(O)-O-(C₁₋₈alkyl)-R¹⁰, -C(O)-NH₂,
 -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -SO₂-(C₁₋₈alkyl), -SO₂-NH₂,
 -SO₂-NH(C₁₋₈alkyl), -SO₂-N(C₁₋₈alkyl)₂, -C(N)-NH₂, -cycloalkyl-R⁸,
 10 -heterocyclyl-R⁹, -aryl-R⁸ and -heteroaryl-R⁹;

- R⁸ is up to 5 substituents independently selected from the group consisting of
 hydrogen, -C₁₋₈alkyl, -C₁₋₈alkoxy, -NH₂, -NH(C₁₋₈alkyl), -N(C₁₋₈alkyl)₂,
 -(C₁₋₈alkyl)-(halo)₁₋₃, -(C₁₋₈alkoxy)-(halo)₁₋₃, -(C₁₋₈alkyl)-OH, cyano, halo,
 15 hydroxy and nitro;

- R⁹ is up to 5 substituents attached to a carbon or nitrogen atom independently
 selected from the group consisting of hydrogen, -C₁₋₈alkyl,
 -(C₁₋₈alkyl)-(halo)₁₋₃ or -(C₁₋₈alkyl)-OH;
 20 with the proviso that, when R⁹ is attached to a carbon atom, R⁹ is further
 selected from -C₁₋₈alkoxy, -NH₂, -NH(C₁₋₈alkyl), -N(C₁₋₈alkyl)₂,
 -(C₁₋₈alkoxy)-(halo)₁₋₃, cyano, halo, hydroxy and nitro;

- R² is selected from the group consisting of -C₁₋₈alkyl-R⁶, -C₂₋₈alkenyl-R⁶,
 25 -C₂₋₈alkynyl-R⁶, -C(O)H, -C(O)-(C₁₋₈alkyl)-R⁶, -C(O)-NH₂,
 -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -C(O)-NH(aryl), -C(O)-cycloalkyl,
 -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -CO₂H,
 -C(O)-O-(C₁₋₈alkyl)-R⁶, -C(O)-O-aryl, -SO₂-(C₁₋₈alkyl)-R⁶, -SO₂-aryl,
 -cycloalkyl-R⁸, -heterocyclyl-R⁹ (attached to the indole nitrogen atom via a
 30 ring carbon atom), -aryl-R⁸ and -heteroaryl-R⁹ (attached to the indole
 nitrogen atom via a ring carbon atom);

R³ is up to 4 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, -C₁₋₈alkyl-R¹⁰, -C₂₋₈alkenyl-R¹⁰, -C₂₋₈alkynyl-R¹⁰, -C₁₋₈alkoxy-R¹⁰, -C(O)H, -C(O)-(C₁₋₈)alkyl-R¹⁰, -C(O)-NH₂,
 5 -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -C(O)-cycloalkyl,
 -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(NH)-NH₂, -CO₂H,
 -C(O)-O-(C₁₋₈)alkyl-R¹⁰, -C(O)-O-aryl, -SO₂-(C₁₋₈)alkyl-R¹⁰, -SO₂-aryl, -N-R⁷,
 cyano, halogen, hydroxy, nitro, -cycloalkyl, -heterocyclyl, -aryl and
 -heteroaryl;

10

R⁴ is up to 4 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, -C₁₋₈alkyl-R¹⁰, -C₂₋₈alkenyl-R¹⁰, -C₂₋₈alkynyl-R¹⁰, -C₁₋₈alkoxy-R¹⁰, -C(O)H, -C(O)-(C₁₋₈)alkyl-R¹⁰, -C(O)-NH₂,
 -C(O)-NH(C₁₋₈alkyl), -C(O)-N(C₁₋₈alkyl)₂, -C(O)-cycloalkyl,
 15 -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(NH)-NH₂, -CO₂H,
 -C(O)-O-(C₁₋₈)alkyl-R¹⁰, -C(O)-O-aryl, -SH, -S-(C₁₋₈)alkyl-R¹⁰,
 -SO₂-(C₁₋₈)alkyl-R¹⁰, -SO₂-aryl, -SO₂-NH₂, -SO₂-NH(C₁₋₈alkyl),
 -SO₂-N(C₁₋₈alkyl)₂, -N-R⁷, cyano, halogen, hydroxy, nitro, -cycloalkyl,
 -heterocyclyl, -aryl and -heteroaryl; and,

20

R¹⁰ is 1 to 2 substituents independently selected from the group consisting of hydrogen, -C₁₋₈alkoxy, -NH₂, -NH(C₁₋₈alkyl), -N(C₁₋₈alkyl)₂, cyano, (halo)₁₋₃, hydroxy, nitro and oxo;

25 and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein R¹ is selected from the group consisting of pyridinyl-R⁵, pyrimidinyl-R⁵, benzothienyl-R⁵ and quinolinyl-R⁵ ring attached to the indole nitrogen atom via a ring carbon
 30 atom.

3. The compound of claim 1 wherein R⁵ is up to 4 substituents independently selected from the group consisting of hydrogen, -(C₁₋₄)alkyl-R⁶, -(C₂₋₄)alkenyl-R⁶, -(C₂₋₄)alkynyl-R⁶, -O-(C₁₋₄)alkyl-R⁶, -O-C(O)H, -O-C(O)-(C₁₋₄)alkyl-R⁶, -O-C(O)-NH₂, -O-C(O)-NH(C₁₋₄alkyl),
5 -O-C(O)-N(C₁₋₄alkyl)₂, -C(O)H, -C(O)-(C₁₋₄)alkyl-R⁶, -CO₂H, -C(O)-O-(C₁₋₄)alkyl-R⁶, -C(O)-NH₂, -C(NH)-NH₂, -C(O)-NH(C₁₋₄alkyl), -C(O)-N(C₁₋₄alkyl)₂, -SH, -S-(C₁₋₄)alkyl-R⁶; -SO₂-(C₁₋₄)alkyl-R⁶, -SO₂-NH₂, -SO₂-NH(C₁₋₄alkyl), -SO₂-N(C₁₋₄alkyl)₂, -N-R⁷, cyano, halo, hydroxy, nitro, -cycloalkyl-R⁸, -heterocyclyl-R⁹, -aryl-R⁸ and -heteroaryl-R⁹.
10
4. The compound of claim 1 wherein R⁵ is up to 4 substituents independently selected from the group consisting of hydrogen and -(C₁₋₄)alkyl-R⁶.
- 15 5. The compound of claim 1 wherein R⁵ is 1 substituent selected from the group consisting of hydrogen and -(C₁₋₄)alkyl-R⁶.
6. The compound of claim 1 wherein R⁶ is up to 2 substituents independently selected from the group consisting of hydrogen,
20 -O-(C₁₋₄)alkyl, -O-(C₁₋₄)alkyl-OH, -O-(C₁₋₄)alkyl-NH₂, -O-(C₁₋₄)alkyl-NH(C₁₋₄alkyl), -O-(C₁₋₄)alkyl-N(C₁₋₄alkyl)₂, -C(O)H, -C(O)-(C₁₋₄)alkyl, -CO₂H, -C(O)-O-(C₁₋₄)alkyl, -C(O)-NH₂, -C(O)-NH(C₁₋₄alkyl), -C(O)-N(C₁₋₄alkyl)₂, -S-(C₁₋₄)alkyl, -SO₂-(C₁₋₄)alkyl, -SO₂-NH₂, -SO₂-NH(C₁₋₄alkyl), -SO₂-N(C₁₋₄alkyl)₂, -N-R⁷, cyano, (halo)₁₋₃,
25 hydroxy, nitro, oxo, -cycloalkyl, -heterocyclyl, -aryl and -heteroaryl.
7. The compound of claim 1 wherein R⁶ is up to 2 substituents independently selected from the group consisting of hydrogen, -N-R⁷, hydroxy and -heteroaryl.
30
8. The compound of claim 1 wherein R⁶ is up to 2 substituents


independently selected from the group consisting of hydrogen, $-N-R^7$, hydroxy and -tetrazolyl.

9. The compound of claim 1 wherein R^7 is 2 substituents independently selected from the group consisting of hydrogen, $-(C_{1-4})alkyl-R^{10}$, $-(C_{2-4})alkenyl-R^{10}$, $-(C_{2-4})alkynyl-R^{10}$, $-C(O)-(C_{1-4})alkyl-R^{10}$, $-C(O)-O-(C_{1-4})alkyl-R^{10}$, $-C(O)-NH_2$, $-C(O)-NH(C_{1-4}alkyl)$, $-C(O)-N(C_{1-4}alkyl)_2$, $-SO_2-(C_{1-4})alkyl$, $-SO_2-NH_2$, $-SO_2-NH(C_{1-4}alkyl)$, $-SO_2-N(C_{1-4}alkyl)_2$, $-C(N)-NH_2$, -cycloalkyl- R^8 , -heterocyclyl- R^9 , -aryl- R^8 and -heteroaryl- R^9 .
10. The compound of claim 1 wherein R^7 is 2 substituents independently selected from the group consisting of hydrogen and $-(C_{1-4})alkyl-R^{10}$.
11. The compound of claim 1 wherein R^8 is up to 5 substituents independently selected from the group consisting of hydrogen, $-C_{1-4}alkyl$, $-C_{1-4}alkoxy$, $-NH_2$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)_2$, $-(C_{1-4})alkyl-(halo)_{1-3}$, $-(C_{1-4})alkoxy-(halo)_{1-3}$, $-(C_{1-4})alkyl-OH$, cyano, halo, hydroxy and nitro.
12. The compound of claim 1 wherein R^8 is hydrogen.
13. The compound of claim 1 wherein R^9 is up to 5 substituents attached to a carbon or nitrogen atom independently selected from the group consisting of hydrogen, $-C_{1-4}alkyl$, $-(C_{1-4})alkyl-(halo)_{1-3}$ and $-(C_{1-4})alkyl-OH$;
with the proviso that, when R^9 is attached to a carbon atom, R^9 is further selected from the group consisting of $-C_{1-4}alkoxy$, $-NH_2$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)_2$, $-(C_{1-4})alkoxy-(halo)_{1-3}$, cyano, halo, hydroxy and nitro.

14. The compound of claim 1 wherein R⁹ is hydrogen.
15. The compound of claim 1 wherein R² is selected from the group consisting of -C₁₋₄alkyl-R⁶, -C₂₋₄alkenyl-R⁶, -C₂₋₄alkynyl-R⁶, -C(O)H,
5 -C(O)-(C₁₋₄)alkyl-R⁶, -C(O)-NH₂, -C(O)-NH(C₁₋₄alkyl), -C(O)-N(C₁₋₄alkyl)₂,
-C(O)-NH(aryl), -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-aryl,
-C(O)-heteroaryl, -CO₂H, -C(O)-O-(C₁₋₄)alkyl-R⁶, -C(O)-O-aryl,
-SO₂-(C₁₋₄)alkyl-R⁶, -SO₂-aryl, -cycloalkyl, -heterocyclyl (attached to the
indole nitrogen atom via a ring carbon atom), -aryl and -heteroaryl
10 (attached to the indole nitrogen atom via a ring carbon atom).
16. The compound of claim 1 wherein R² is selected from the group consisting of -C₁₋₄alkyl-R⁶ and heteroaryl.
- 15 17. The compound of claim 1 wherein R³ is up to 4 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, -C₁₋₄alkyl-R¹⁰, -C₂₋₄alkenyl-R¹⁰, -C₂₋₄alkynyl-R¹⁰,
-C₁₋₄alkoxy-R¹⁰, -C(O)H, -C(O)-(C₁₋₄)alkyl-R¹⁰, -C(O)-NH₂,
-C(O)-NH(C₁₋₄alkyl), -C(O)-N(C₁₋₄alkyl)₂, -C(O)-cycloalkyl,
20 -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(NH)-NH₂, -CO₂H,
-C(O)-O-(C₁₋₄)alkyl-R¹⁰, -C(O)-O-aryl, -SO₂-(C₁₋₄)alkyl-R¹⁰, -SO₂-aryl,
-N-R⁷, cyano, halogen, hydroxy, nitro, -cycloalkyl, -heterocyclyl, -aryl and
-heteroaryl.
- 25 18. The compound of claim 1 wherein R³ is hydrogen.
19. The compound of claim 1 wherein R⁴ is up to 4 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, -C₁₋₄alkyl-R¹⁰, -C₂₋₄alkenyl-R¹⁰, -C₂₋₄alkynyl-R¹⁰,
30 -C₁₋₄alkoxy-R¹⁰, -C(O)H, -C(O)-(C₁₋₄)alkyl-R¹⁰, -C(O)-NH₂,
-C(O)-NH(C₁₋₄alkyl), -C(O)-N(C₁₋₄alkyl)₂, -C(O)-cycloalkyl,

- 5 -C(O)-heterocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(NH)-NH₂, -CO₂H,
 -C(O)-O-(C₁₋₄)alkyl-R¹⁰, -C(O)-O-aryl, -SH, -S-(C₁₋₄)alkyl-R¹⁰,
 -SO₂-(C₁₋₄)alkyl-R¹⁰, -SO₂-aryl, -SO₂-NH₂, -SO₂-NH(C₁₋₄alkyl),
 -SO₂-N(C₁₋₄alkyl)₂, -N-R⁷, cyano, halogen, hydroxy, nitro, -cycloalkyl,
 -heterocyclyl, -aryl and -heteroaryl.

20. The compound of claim 1 wherein R⁴ is hydrogen.
21. The compound of claim 1 wherein R¹⁰ is 1 to 2 substituents
 10 independently selected from the group consisting of hydrogen,
 -C₁₋₄alkoxy, -NH₂, -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)₂, cyano, (halo)₁₋₃, hydroxy,
 nitro and oxo.
22. The compound of claim 1 wherein R¹⁰ is hydrogen.
23. The compound of claim 1 wherein the compound of Formula (I) is
 15 selected from a compound of Formula (Ia):



Formula (Ia)

wherein R¹ and R² are selected from the group consisting of

R ¹	R ²
3-pyridinyl	-(CH ₂) ₂ -OH;
5-pyrimidinyl	-(CH ₂) ₂ -OH;
3-quinolinyl	-(CH ₂) ₂ -OH;
3-pyridinyl	-(CH ₂) ₃ -OH;

R ¹	R ²
3-benzo(<i>b</i>)thienyl	-(CH ₂) ₃ -NMe ₂ ;
5-pyrimidinyl	-CH ₃ ;
3-pyridinyl	-CH ₃ ;
3-pyridinyl	-(CH ₂) ₂ -tetrazol-2-yl;
3-pyridinyl	-(CH ₂) ₂ -tetrazol-1-yl;
	and
3-pyridinyl	3-pyrimidinyl

and pharmaceutically acceptable salts thereof.

24. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 5
25. A method for preparing a composition comprising mixing a compound of claim 1 and a pharmaceutically acceptable carrier.
- 10 26. A method for treating or ameliorating a kinase mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.
- 15 27. The method of claim 26 wherein the disorder is mediated by selective inhibition of a kinase selected from the group consisting of protein kinase C and glycogen synthase kinase-3.
- 20 28. The method of claim 27 wherein the kinase is selected from the group consisting of protein kinase C α , protein kinase C β -I, protein kinase C β -II, protein kinase C γ and glycogen synthase kinase-3 β .
29. The method of claim 26 wherein the disorder is mediated by dual inhibition of at least two kinases selected from the group consisting of

protein kinase C and glycogen synthase kinase-3.

30. The method of claim 29 wherein at least two kinases are selected from the group consisting of protein kinase C α , protein kinase C β -II, protein
5 kinase C γ and glycogen synthase kinase-3 β .
31. The method of claim 26 wherein the therapeutically effective amount of the compound of claim 1 is from about 0.001 mg/kg/day to about 300 mg/kg/day.
10
32. The method of claim 26 wherein the kinase mediated disorder is selected from the group consisting of cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and CNS
15 disorders.
33. The method of claim 32 wherein cardiovascular diseases are selected from the group consisting of acute stroke, heart failure, cardiovascular ischemia, thrombosis, atherosclerosis, hypertension, restenosis,
20 retinopathy of prematurity and age-related macular degeneration.
34. The method of claim 32 wherein diabetes is selected from the group consisting of insulin dependent diabetes and Type II non-insulin dependent diabetes mellitus.
25
35. The method of claim 32 wherein diabetes-associated disorders are selected from the group consisting of impaired glucose tolerance, diabetic retinopathy, proliferative retinopathy, retinal vein occlusion, macular edema, cardiomyopathy, nephropathy and neuropathy.
30
36. The method of claim 32 wherein inflammatory diseases are selected

from the group consisting of vascular permeability, inflammation, asthma, rheumatoid arthritis and osteoarthritis.

- 5 37. The method of claim 32 wherein immunological disorders are selected from the group consisting of transplant tissue rejection, HIV-1 and PKC modulated immunological disorders.
- 10 38. The method of claim 32 wherein dermatological disorders are selected from the group consisting of psoriasis, hair loss and baldness.
39. The method of claim 32 wherein oncological disorders are selected from the group consisting of cancer or tumor growth, proliferative angiopathy and angiogenesis.
- 15 40. The method of claim 32 wherein central nervous system disorders are selected from the group consisting of chronic pain, neuropathic pain, epilepsy, chronic neurodegenerative conditions, dementia, Alzheimer's disease, mood disorders, schizophrenia, manic depression and neurotraumatic, cognitive decline and ischemia-related diseases (as a
- 20 result of head trauma or transient ischemic stroke).
41. The method of claim 26 further comprising a method for use for a compound of claim 1 as an adjunct to chemotherapy and radiation therapy.
- 25 42. The method of claim 26 further comprising administering to a subject in need thereof a therapeutically effective amount of a composition of claim 24.

43. The method of claim 26 wherein the therapeutically effective amount of a composition of claim 24 is from about 0.001 mg/kg/day to about 300 mg/kg/day.

5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/17569

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/14 C07D403/14 C07D409/14 A61K31/404 A61K31/4025
 A61K31/4439 A61K31/506 A61P7/02 A61P9/00 A61P17/00
 A61P25/00 A61P37/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 11102 A (BERGSTRAND HAAKAN ;ASTRA AB (SE); HOEGBERG THOMAS (SE); TUNEK ANDE) 19 March 1998 (1998-03-19) claims 2,12-14 examples 16,17,20 ---	1,24
X	EP 1 057 484 A (ASAKAI REI ;SAGAMI CHEM RES (JP)) 6 December 2000 (2000-12-06) claims 1,2,6,9,10,14,16 page 5, line 58 -page 6, line 3 ---	1,24
A	WO 95 17182 A (LILLY CO ELI) 29 June 1995 (1995-06-29) examples 8,48,64,71 claims 3,4,9,10 --- -/--	1,24

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
 E earlier document but published on or after the international filing date
 L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 O document referring to an oral disclosure, use, exhibition or other means
 P document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 & document member of the same patent family

Date of the actual completion of the international search

23 September 2003

Date of mailing of the international search report

08/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/17569

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DAVIS P D ET AL: "INHIBITORS OF PROTEIN KINASE C 1. 2,3-BISARYLMALEIMIDES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 1, 1992, pages 177-184, XP000910195 ISSN: 0022-2623 abstract; example 16 -----	1,24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/17569

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 26-43 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/17569

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9811102	A	19-03-1998	AU 718844 B2	20-04-2000
			AU 4143197 A	02-04-1998
			EP 0925296 A1	30-06-1999
			NZ 334201 A	23-02-2001
			WO 9811102 A1	19-03-1998
			US 6153641 A	28-11-2000
			ZA 9707807 A	10-03-1998
EP 1057484	A	06-12-2000	AU 2548699 A	06-09-1999
			EP 1057484 A1	06-12-2000
			WO 9942100 A1	26-08-1999
WO 9517182	A	29-06-1995	US 5545636 A	13-08-1996
			AU 1339895 A	10-07-1995
			CA 2179650 A1	29-06-1995
			EP 0817627 A1	14-01-1998
			JP 9507066 T	15-07-1997
			WO 9517182 A1	29-06-1995
			US 5661173 A	26-08-1997
			US 5672618 A	30-09-1997
			US 5668152 A	16-09-1997
			ZA 9410139 A	20-06-1996